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The primary goals of our research are to understand the virology and enzymology 
of human T-cell leukemia virus type I (HTLV-I) that will lead to the development of 
treatments for patients infected with HTLV-I. HTLV-I is an oncogenic virus of the 
Retroviridae family and is the causative agent of adult T-cell leukemia/lymphoma (ATL), 
tropical spastic paraparesis/HTLV-I associated myelopathy (TSP/HAM). HTLV-I has 
been classified as a dangerous emerging pathogen by the Centers for Disease Control & 
Prevention with at least 20 million people infected with the virus. This is a significant 
problem because there are currently no effective treatments to control HTLV-I infection 
and prevent or treat HTLV-I induced ATL and TSP/HAM. 
The protease is necessary for retroviral maturation and replication and is, 
therefore, an attractive target for inhibitor design.  Investigation of peptide mimetic 
compounds incorporating the tetrahedral intermediate of aspartyl protease catalyzed 
cleavage are crucial for the development of lead inhibitors. Compounds containing 
statine, 4-amino-3-hydroxy-5-phenylpentanoic acid (AHPPA), or hydroxyethylamine 
(HEA) are presented in this work. The best compound was a statine-based inhibitor, 
which had a Ki = 29 ± 4 nM and 88% inhibition against an HTLV-I protease native 











1.1 Human T-Cell Leukemia Virus Type I 
 
 
  Human T-Cell Leukemia Virus Type I (HTLV-I) is an oncogenic virus of the 
Retroviridae family (Murphy & Kingsbury, 1990). HTLV-I has been etiologically 
implicated as the causative agent of adult T-cell leukemia/lymphoma (ATL) (Gitlin et al., 
1993), tropical spastic paraparesis/HTLV-I associated myelopathy (TSP/HAM) (Gessain 
et al., 1985), and other diseases such as uveitis, infectious dermatitis, polymyositis, and 
polyarthritis (Gessain, 1996). 
 In 1978, HTLV was isolated from cultured CD4+ T-lymphocytes from a patient in 
the United States with cutaneous T-cell lymphoma (Gallo & Thomson, 1996; Poiesz et 
al., 1980). A second isolate was obtained from a different patient with CD4+ T-cell 
leukemia (Gallo & Thomson, 1996). Independently, a similar virus described as Adult T-
Cell Leukemia Virus (ATLV) was isolated from an adult T-cell leukemia/lymphoma 
patient in Japan. The name HTLV-I was adopted for both HTLV and ATLV as a result of 
the homology of the viral genome and antigens (Gallo & Thomson, 1996; Gitlin et al., 
1993; Yoshida et al., 1982; Yoshida et al., 1984). 
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  HTLV-I is endemic in southwestern Japan (Gallo & Thomson, 1996; Green & 
Chen, 1993), as well as areas in the Carribean, sub-Saharan Africa, Seychelles Islands, 
Melanesia, Australia, Philippines, the Americas, south India, and southwestern Asia 
(Gallo & Thomson, 1996). Worldwide estimates are that approximately 20 million people 
are infected with HTLV-I (Dekaban et al., 1992). In the United States, there is an 
estimated  prevalence of 0.016-0.1% HTLV-I infection among blood donors (Zucker-
Franklin & Pancake, 1998). Transmission is vertical via maternal breast milk, 
intravenous drug use with contaminated sharps, transfusion with infected blood, and 
sexual transmission (Gessain, 1996; Kaplan & Khabbaz, 1993; Khabbaz et al., 1990). 
Sexual transmission is much more efficient from male to female (60.8%) than from 
female to male (0.4%) (Gitlin et al., 1993), therefore, a disproportionately higher number 






1.2  Transmission of HTLV-I Virions 
 
 
The model of retroviral infection suggests that virus particles recognize and bind 
to specific target cells. This recognition and binding occurs through interactions between 
the envelope glycoprotein complex (Env) and a surface receptor. This results in 
adhesion of the cell and the viral membranes, which leads to the virus core being 
deposited into the host cell cytoplasm (Derse & Heidecker, 2003). This model has 
recently been challenged for HTLV-I. It appears that cell-to-cell contact is essential for 
viral transmission (Derse & Heidecker, 2003; Igakura et al., 2003).  
The viral envelope glycoprotein complex consists of two proteins, the 
glycosylated hydrophilic surface protein (SU) and a transmembrane protein (TM). 
Together, these proteins form the spikes on the surface of the virus. Both proteins are 
proteolytically cleaved from the Env precursor protein upon transfer to the cell surface. 
Neither of these proteins are necessary for envelope assembly, however they do have a 
role in the entry process (Coffin et al., 1997). The SU specifically binds to a specific cell 
receptor. This binding association appears to trigger the membrane fusion-inducing 
potential of the TM, which then results in the fusion of cell and virus membranes (Derse 
& Heidecker, 2003; Coffin et al., 1997). 
The precise mechanism of cell-to-cell infection is not well understood. The 
receptor to which the Env bind has not been identified. However, it has been 
demonstrated that the HTLV-I core (Gag) proteins along with the HTLV-I genome 
accumulate at the cell-to-cell junction and are subsequently transferred to an uninfected 





To date, HTLV-I is the only retroviral agent known to cause human cancer.  
HTLV-II, which is the other known human oncovirus, is not linked with cancer. Like HIV, 
HTLV-I targets CD4+ T-cells. The main pathological difference between HTLV-I and HIV 
is that HTLV-I alters the cells, which may result in tumor growth and other neurological 
disorders, while HIV destroys CD4+ T-cells. Both HTLV-I and HIV have regions in their 
genomes that encode Gag, Pol, and Env polyprecursors, as well as accessory proteins 
that appear to be necessary for viral infectivity in vivo. The 3’ end of HTLV-I has a pX 
region that has four open reading frames (ORFs), (Johnson and Franchini, 2002). It is 
this pX region that has placed HTLV-I into a unique class of retroviruses that includes 
HTLV-II and bovine leukemia virus (BLV), (Yoshida and Seiki, 1990), which is the 
etiologic cause of enzootic bovine leucosis (Coffin et al., 1997). The first ORF codes for 
a small hydrophobic protein, p12I. This protein, similar to HIV-1 Nef, is membrane-
associated and is required for in vivo infectivity but not in vitro replication (Johnson and 
Franchini, 2002). 
HTLV-I has the ability to infect a wide range of cell types. However, it is the T-
cells and B-cells that are prone to transformation. Therefore, the T-cell lymphocyte 
tropism appears to be induced by post-infectivity events rather than at the receptor level 





1.4   Diseases Associated with HTLV-I 
 
 
ATL is a malignancy of mature CD4+ T-lymphocytes and is characterized by 
“lymphoma/leukemia often associated with generalized lymphadenopathy, 
hypercalcemia, infiltrative skin lesions, hepatosplenomegaly, bone marrow involvement, 
and lytic bone lesions of the skull and long bones” (Gitlin et al., 1993). Malignant 
lymphocytes found in the peripheral blood of HTLV-I infected individuals can be 
characterized by irregular nuclei referred to as “flower cells.”  ATL is a progressive 
disease with four stages:  pre-ATL (preleukemia), smoldering ATL, chronic ATL, and 
acute or subacute ATL.  Pre-ATL individuals are typically diagnosed with abnormal 
lymphocytes. However, few apparent symptoms are displayed.  An estimated 30% of 
pre-ATL patients progress to the smoldering and chronic ATL stages with indicative skin 
lesion formation.  Further progression to the acute stage may occur in a few months and 
is indicated by aggressive CD4+ T-lymphocyte malignancy (Gitlin et al., 1993). ATL is the 
most prevalent disease caused by HTLV-I with 20-30 years for progression following 
viral infection (Green & Chen, 1993). 
TSP/HAM is a neurological demyelinating disease.  Affected individuals 
generally display abnormal muscle movement of the extremities and some sensory loss 
(Gitlin et al., 1993).  TSP/HAM differs from ATL in that individuals may develop 
TSP/HAM disease in a matter of a few years following infection with HTLV-I rather than 




1.5 Current Treatment of HTLV-I 
 
 
 Currently, there is no adequate treatment for HTLV-I infected individuals. 
Combination therapies have been tried, with limited success. For example, the 
OPEC/MPEC treatment protocol (weekly doses of vincristine, methotrexate, 
prednisolone, etoposide, and cyclophosphamide) or daily doses of etoposide and 
prednisolone (DOEP) has had a limited impact. The median survival time (MST) of all 
infected patients and those with acute leukemia, lymphoma and progressive chronic 
leukemia was 7.5-12.4 months. The MST for patients treated with the OPEC/MPEC 
regimen was 7.1 months while the MST for patients taking the DEOP regimen was 18.0 
months (Matsushita et al., 1999). 
 
 
1.6  Significance 
 
 
   HTLV-I was the first human oncogenic retrovirus to be discovered. Even though 
HTLV-I has been classified as a dangerous emerging pathogen by the Centers for 
Disease Control & Prevention, it is not as well understood as HIV-1 (Ewald, 1996; 
Satcher, 1995). Approximately 10% of the estimated 15-20 million individuals infected 
with HTLV-I will develop the fatal disease ATL. (Gessain, 1996; Zucker-Franklin & 
Pancake, 1998). This is a significant problem because there are currently no effective 
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treatments to control HTLV-I infection and prevent or treat HTLV-I induced ATL and 
TSP/HAM.  
The protease is necessary for retroviral maturation and replication and is, 
therefore, an attractive target for inhibitor design.  However, not much is known about 
the structure and enzymology of HTLV-I protease. It is crucial for the designing of 
inhibitors of HTLV-I protease to have a structural understanding of the sterics and 
electronic interactions necessary for binding to HTLV-I protease active site in order to 
design high affinity inhibitor drugs. Since there is no known structure of HTVL-I protease, 
a theoretical model of this protease was used to better understand the binding 
interactions of the active site and thus facilitate design of effective inhibitors (Dennison et 
al., 2003; Herger, 2004).  
Investigation of peptide mimetic compounds that incorporate the tetrahedral 
intermediate of aspartyl protease catalyzed-cleavage is can provide for the development 
of lead inhibitors. Compounds containing statine, 4-amino-3-hydroxy-5-phenylpentanoic 
acid (AHPPA), or hydroxyethylamine (HEA) are expected to be potent protease 
inhibitors with Ki < 1 nM. 
HTLV-I protease contains ten C-terminal residues that are not conserved across 
non-leukemic retroviral proteases. Leu115 and Pro116 form a prototypical cleavage site 
(L/P) in the C-terminal tail domain and should result in autoprocessing comparable to the 
non-leukemic proteases. The cleavage at this site is inhibited by Tyr114 or Glu117, which 
occupy the putative P2 and P2’ substrate position, respectively.  Catalysis experiments 
with HTLV-I and peptide mutants incorporating mutations in the P2 and P2’ (Tyr and Glu, 
respectively) could provide answers to why this C-terminal tail remains intact and could 
provide additional understanding of HTLV-I protease enzymology. 
 8 
A second site for treatment is the HTLV-I nucleocapsid protein. Not much is 
known about the structure of the nucleocapsid protein that is processed from the Gag 
precursor polyprotein. The primary role of the nucleocapsid is in recognition and 
packaging of the viral genome (Lee et al., 1998; Amarasinghe et al., 2000; Williams et 
al., 2002; Coffin et al., 1997). HIV-1 nucleocapsid structure has been determined and 
several nucleocapsid inhibitors are being developed (Amarasinghe et al., 2000; Lee et 
al., 1998; Stephen et al., 2002). However, the structure of HTLV-I nucleocapsid has not 
yet been reported. Determining the three-dimensional structure of this important protein 
would enable the development of alternative drug therapies for the treatment of HTLV-I 
infections.  
 The primary aims of this work were to examine the protease activity of 
synthesized 10-mer peptides that incorporate a possible C-terminal tail cleavage site, to 
explore the in vivo behavior of HTLV-I L40I mutant protease and the L40I mutant without 
the last 10 C-terminal residues (L40I10); to prepare pentapeptides incorporating 
statine, AHPPA, or HEA isosteric mimetics of the tetrahedral intermediate of aspartyl 
protease-catalyzed peptide cleavage; to test inhibition of the peptide mimetics in an in 
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            HTLV-I GENOMIC STRUCTURE 
 
        2.1 Viral Assembly 
 
 
  The transfer of an infectious virus requires the assembly of its structure. Proteins 
comprising the retrovirus are expressed from an RNA genome, via a DNA intermediate, 
as precursor polyproteins: Gag, Gag-Pro-Pol, and Env. These polyproteins are derived 
from the group-specific antigen (gag), the protease (pro), the polymerase (pol), and the 
envelope (env) genes on the RNA genome (Koralnik, 1996; Coffin et al., 1997). The 
expressed polyproteins are proteolytically cleaved to generate the internal and structural 
proteins. The spherical core proteins of oncoviruses or the conical core proteins of 
lentiviruses consist of the matrix (MA), capsid (CA), and nucleocapsid (NC), which are 
associated with the Gag precursor. The protease (PR) is associated with the Gag-Pro 
and Gag-Pro-Pol precursors and reverse transcriptase (RT) and integrase (IN) are 
associated only with the Gag-Pro-Pol precursor (Coffin et al., 1997).  The envelope 
proteins of the surface (SU) and the transmembrane (TM) are associated with the Env. 




Figure 2.1 General retroviral protein components. Abstracted from Coffin et al. 
Retroviruses, 1997 (NC = nucleocapsid, Su = surface, TM = transmembrane, RT = 
reverse transcriptase, CA = capsid, MA = matrix, PR = protease, IN  = integrase). 
 
Figure 2.2 shows an illustration of typical retroviral assembly. Assembly begins 
with the viral transcripts used to synthesize the Gag and Gag-Pro-Pol polyproteins and 
ends with the immature budding virion followed by protease processing to form the 








  The budding process is facilitated by myristylation of the MA-end of the Gag, 
Gag-Pro, and Gag-Pro-Pol precursors. These precursors then migrate toward the host 
cell lipid bilayer. The unprocessed proteins are assembled into a spherical shell and 






2.2 HTLV-I Precursor Proteins 
 
 
The proviral genome of HTLV-I is 9033 base pairs in length (Zhao et al., 1993) 
and has been isolated and cloned from the leukocytes of ATL patients. The subsequent 
characterization of the genome revealed that it is composed of gag, pol, pro, and env, 
genes as previously described (Kobayashi et al., 1991; Koralnik, 1996). Additionally, 
HTLV-I has two non-structural genes, tax and rex that code for regulatory proteins 
involved in synthesis and processing of the viral RNA (Murphy & Kingsbury, 1990). The 
genes are flanked by long terminal repeats (LTRs) which are divided into three 
sequences: U3, U5, and R (Figure 2.3). U3 and U5 relate to sequences at the 3’ and 5’ 
ends of the RNA genome and R relates to a sequence repeated at both 3’ and 5’ end 
(Coffin et al., 1997). The LTRs are formed in the 3’ to 5’ direction with U3-R-U5 during 
DNA synthesis. As illustrated in Figure 2.3, the proviral DNA is considerably longer than 
the original full-length viral RNA. The LTRs contain strong promoter and enhancer 
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The open reading frame (ORF) of the protease is located between the gag and 
pol genes. The gag, pro, pol organization of HTLV-I is different than that of HIV-1 (Figure 
2.4). The ORF is shifted in the –1 direction of the pro-pol (pro is the 5’ end of pol) from 
gag in HIV. In HTLV-I, the gag, pro, pol are separate genes encoded in different ORFs. 
In HTLV-I, the pro is frame shifted in the –1 direction from gag and pol is shifted in the –
1 direction from pro. In HTLV-I, there are two ribosomal frame shifts for the gag-pol 
overlap and the pro-pol overlap that are necessary for synthesis of the pol-encoded 
HTLV-I replication enzymes (Ding et al., 1998). The 5’ end of the env ORF overlaps with 
the 3’ end of pol (Koralnik, 1996). 
 
 
Figure 2.4 Schematic representation of the major genes for HTLV-I and HIV. The 
scale is in kilobases (kB) shown at the top of the diagram. The “Reading Frame” 
refers to the translation frame of the illustrated genes relative to gag, arbitrarily 
assigned as the 0 position. Note: Only major genes are shown. Adapted from Ding et 
al.,1998. 
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The occurrence of the two frame shifts is required for the replication of the virus 
(Nam et al., 1988).  Translation of the genome yields four large fusion proteins: Gag, 
Gag-Pro, Gag-Pro-Pol, and Env (Nam et al., 1993; Carrington & Schulz, 1996; Koralnik, 
1996). The protease is necessary for cleavage of these polyprecursor proteins into the 
mature products as shown in Figure 2.5.  
 
 














Figure 2.5 Products of genomic translation and processing. 
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Figure 2.6 shows the one-letter amino acid sequences of the Gag, Gag-Pro, and 









































Figure 2.6 Gag, Gag-Pro, and Gag-Pro-Pol fusion proteins taken from HTLV-I K30 
clone, GenBank Accession L03562. Colors indicate protein product sequences. Stops 





 Cleavage of the Gag protein by HTLV-I protease yields proteins: p19 MA (130 
amino acids), p24 CA (214 amino acids), and p15 NC (85 amino acids) p19, p24, and 
p15 signify that these proteins are 19 kDa, 24 kDa, and 15 kDa, respectively (Koralnik, 
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1996). The protease is derived from Pro and proteolytic cleavage of the Pol results in the 
RT and IN production (Nam et al., 1993; Nam et al., 1988; Nam & Hatanaka, 1986). The 
Env precursor is glycosylated and then processed by exopeptidases to yield the 46 kDa 
SU and 21 kDa TM envelope glycoproteins (Coffin et al., 1997). 
The exact mechanism for how the protease cleaves itself from the Gag-Pro-Pol 
and Gag-Pro has not been resolved. For HIV, it has been shown that the protease is 
active as a dimer (Coffin et al., 1997; Oroszlan & Luftig, 1990).  The concentration of the 
Gag-Pol precursor protein may actually facilitate dimerization. Therefore, it is highly 
likely that initial proteolytic cleavage is carried out by the dimerization of two Gag-Pol 
precursor proteins within the immature protease (Coffin et al., 1997; Pettit et al., 2003). 
The development of protease inhibitors that disrupt this proteolytic processing is an 
attractive target and should be an effective strategy for rational drug design that will 
provide significant advancement in the treatment of HTLV-I related diseases. 
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Retroviral proteases are aspartyl proteases. These proteases have two aspartic 
acid residues in the active site that participate in the hydrolysis of peptides (Figure 3.1). 
The catalytic mechanism follows general acid-base catalysis. It is widely accepted that 
the carboxyl group of one of the aspartic acid residues is protonated while the second 
one is deprotonated upon substrate binding. The general scheme of catalysis is shown 
in Figure 3.2. The first step of the mechanism involves two concerted proton transfers, 
which facilitate nucleophilic attack by a water molecule on the substrate carbonyl carbon 
to form a tetrahedral intermediate. In the third step, the aspartate residue is protonated 
by one of the hydroxyl group from the tetrahedral intermediate, and the amine to be 
cleaved accepts a proton from the other aspartic acid residue (Garrett & Grisham, 1995). 
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Figure 3.1 Structure of HIV-1 protease (PDB: 1A94). One monomer is colored in 

























































Figure 3.2 Mechanism of aspartic acid protease-catalyzed peptide cleavage.
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HTLV-I protease was isolated by Hatanaka in the late 1980’s (Hatanaka & Nam, 
1989) and by Daenke in the early 1990’s (Daenke et al., 1994). HTLV-I protease is a 
homodimer aspartyl protease that has a conserved Asp-Thr-Gly catalytic site in the core 
active site region (Kobayashi et al., 1991).  Several crystal structures have been 
determined for HIV-1, Rous Sarcoma Virus (RSV), and Feline Leukemia Virus (FIV) 
proteases (Gustchina et al., 1996; Louis et al., 1999).  However, the structure of HTLV-I 
protease has not yet been determined. BLV protease has 32% identity with HTLV-I 
protease (Précigoux et al., 1993), making it the most homologous of all the retroviral 
proteases (Shuker et al., 2003). However, the three-dimensional structure of BLV 





Table 3.1 Homology of HTLV-I protease with other retroviral aspartic acid proteases. “Length” refers to the number of 







 length HTLV-I HTLV-2 BLV MuLV RSV HIV-1 HIV-2 SIV FIV EIAV 
HTLV-I 125 - 50% 36% 21% 25% 28% 29% 32% 23% 26% 
HTLV-2 125 50% - 33% 2% 23% 26% 24% 26% 21% 25% 
BLV 126 36% 33% - 27% 23% 24% 25% 25% 21% 26% 
MuLV 125 21% 25% 27% - 21% 23% 24% 27% 25% 24% 
RSV 124 25% 23% 23% 21% - 30% 26% 25% 26% 26% 
HIV-1 99 28% 26% 24% 23% 30% - 48% 50% 25% 29% 
HIV-2 99 29% 24% 25% 24% 26% 48% - 86% 24% 33% 
SIV 99 32% 26% 25% 27% 25% 50% 86% - 22% 35% 
FIV 113 23% 21% 21% 25% 26% 25% 24% 22% - 30% 
EIAV 104 26% 25% 26% 24% 26% 29% 33% 35% 30% - 
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Figure 3.3 shows a sequence alignment with several aspartyl proteases: HTLV-I, 
BLV, RSV, HIV-1, HIV-2, and FIV. It is worth noting that the HTLV proteases have a long 
hydrophobic C-terminal “tail” that is only present in leukemia viral proteases (Herger, 
2004; Shuker et al., 2003). Each chain of HTLV-I protease has 125 amino acid residues 
(115 without the “tail”), BLV has 126 amino acids (116 without the “tail”), RSV has 124 










Figure 3.4 shows a comparison of the backbones of the known HIV-1, HIV-2, and 
RSV protease structures superimposed. As can be seen in the Illustration, the backbone 
folds of the proteases are highly conserved.  
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Figure 3.4 Superimposed backbone structures of HIV-1 (magenta), HIV-2 (green), 





For proteins with no NMR or X-ray crystal structure, molecular modeling can be a 
very useful tool for understanding the three-dimensional structure. A good theoretical 
model should be determined by using a template with high resolution, minimal disorder, 
and a highly complete data collection set. In finding a suitable template structure for 
modeling HTLV-I protease, it is necessary to find a sequence with as much homology as 
possible. HIV-1 protease has less than 30% homology. In addition, the amino acid 
sequence differences between HIV-1 and HTLV-I proteases have been shown to 
produce differences in the activities of the enzymes; there are different specificities 
exhibited for protease inhibitors (Daenke et al., 1994; Hruskova-Heidingsfeldova et al., 
1997; Kobayashi et al., 1991).   
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Crystal structures available as templates for HTLV-I protease are limited to RSV 
and HIV-1 protease structures deposited in the Protein Data Bank, which have low levels 
of homology. RSV protease bears a 21% sequence homology with HTLV-I protease, 
while HIV-1 protease is 28% homologous. However, RSV protease does have a region 
in the upper flap (RSV sequence: Gly-Ser-His-Pro-Val-Lys-Gln-Arg-Ser-Val) that is 
similar in number of residues to the corresponding HTLV-I protease region (HTLV-I 
sequence: Thr-Ser-His-Pro-Lys). These sequences are underlined with asterisks in 
Figure 3.5. This additional sequence of amino acids is absent in HIV-1 protease.  Figure 
3.5 also shows the extended outer loop residues (underlined with circles) of HTLV-I and 
RSV compared to the missing residues in HIV. Amino acides in color are the conserved 
homologous amino acids of RSV and HIV proteases compared with HTLV-I.  
 
 
HTLV-I wt  PVIPLDPAR-RPVIKAQVDTQTSHP-K----TIEALLDTGADMTVLPIALFSSNT--- 
RSV 1BAI   LAMTMEHKD-RPLVRVILTNTGSHPVKQRSVYITALLDTGADDTVISEEDWPTDWPVM 
HIV-1 1D4L --PQITLWK-RPLVTIRIGGQ----------LKEALLDTGADDTVIEEMNLPG----- 
            ********** 
 
HTLV-I WT  PLKN--TSVLGAGGQTQDHFKLTSLPVLIRLPFRTTPIVLTSCLVDTKNNWA- 
RSV 1BAI   EAANPQIHGIGGGIPVRKSRDMIELGVINRDGSLERPLLLFPLVAMTPVN--- 
HIV-1 1D4L KWKP--KMIGGIGG-----FIKVRQYDQIPVEIXGHKAIGTVLVGPTPVN--- 
     •••••• 
 
HTLV-I wt  IIGRDALQQCQGVLYLPEAKGPPVIL Key 
RSV 1BAI   ILGRDCLQGLGLRLTNL--------- Hydrophobic 




Figure 3.5 Sequence alignment of HTLV-I, RSV, and HIV proteases. Asterisks 





In addition, it can be seen in Figure 3.5 that part of the upper flap region (RSV 
sequence: Pro-Val-Arg-Lys-Ser and HTLV-I sequence: Gln-Thr-Gln-Asp-His) is absent in 
HIV protease. Figure 3.6 shows a secondary structure map of RSV protease, illustrating 
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where the β-sheets and α-helices are located relative to the residue positions. This 
cartoon demonstrates typical retroviral protease secondary structure.  
  
Figure 3.6 Schematic of secondary structural elements in retroviral proteases. Magenta  
arrows indicate β-sheets, blue coils are α-helices, and pink are random coils. Abstracted 





3.3 Theoretical Model of HTLV-I Protease 
 
 
A theoretical model of HTLV-I protease (PDB 1O0J) (Herger, 2004) (Dennison 
et al., 2003) was generated using the program Modeller (Fiser et al., 2000; Marti-Renom 
et al., 2000; Sali & Blundell, 1993). This structure was modeled with RSV protease (PDB 
1BAI) (Figure 3.7) serving as a structural template (Tözsér et al., 2000). This template 
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was chosen based on the quality of the published structure, as well as homology. For 
the crystal structure, RSV protease was crystallized with an HIV-1 protease 
peptidomimetic CA/p2 analog (Arg-Val-Leu-Nle-Phe-Glu-Ala-NH2, Nle = norleucine, a 




    Figure 3.7 RSV protease (PDB 1BAI) with ligand (RVL-Nle-FEA-NH2 shown as blue 






The RSV protease structure used as the template was refined at 2.4 Å. This 
crystal had 9 mutations (S38T, I42D, I44V, M73V, A100L, V104T, R105P, G106V, and 
S107N) to mimic HIV-1 protease. The data set was 76.8% complete. The final structure 




had one dimer and one inhibitor in the asymmetric unit (Mahalingam et al., 1999; Weber 
et al., 1997; Wu et al., 1998).  
Docking of the CA/NC (TKVLVVQP) HTLV-I substrate was accomplished by 
superimposing the MODELLER structure prepared by Bryan Herger over the RSV/RSV 
ligand complex using Molecular Operating Environment (MOE) (Chemical Computing 
Group). The RSV substrate was then mutated into the CA/NC HTLV-I substrate and 
subsequently minimized. This theoretical model (PDB 1O0J), based on our previous 
alignment, is shown in Figure 3.8  (Herger et al., 2004) and the superimposed theoretical 
model with HIV and RSV is shown in Figure 3.9. It is important to note that HTLV-I 
protease has an additional ten C-terminal residues that are not present in RSV protease 
and are therefore not included in the published PDB 1O0J structure.  
 
Figure 3.8  Theoretical model of HTLV-I protease (PDB 1O0J) with CA/NC substrate 





Figure 3.9 Superimposed backbone structures of theoretical HTLV-I protease model   











HTLV-I protease cleaves long chains of amino acids (the polyfusion proteins or 
precursor proteins) encoded by the gag, gag-pro, and gag-pro-pol, genes. There are 
several specific cleavage points along these chains of amino acids (called the scissile 
bonds) that bind tightly to HTLV-I protease as natural substrates. Figure 2.6 shows an 
illustration of the transcribed Gag, Gag-Pro, and Gag-Pro-Pol fusion proteins prior to 
proteolysis by HTVL-I protease. These substrates are then cleaved into smaller chains 
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of amino acids that form the MA, CA, NC, RT-RH, IN, and PR proteins (Coffin et al., 
1997). Some of these specific cleavage site substrates are shown in Table 3.2.  
There are eight binding pockets in the active site of retroviral proteases. From 
scissile site moving toward the right, the pocket is numbered S1’, S2’, S3’, S4’…and the 
substrate is numbered P1’, P2’, P3’, P4’…From the scissile site moving toward the left, 
the pocket is numbered S1, S2, S3, S4…and the substrate is numbered P1, P2, P3, 





 Figure 3.10  Schematic diagram of substrate positions and binding pockets.  Circles 
represent substrate amino acids, and arcs represent sites on the protease.  The scissile 
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MA/CA PQVL/PVMH PAIL/PIIS -- VVAM/PVVI SQNY/PIVQ PQAY/PIQT SEEY/PIMI 
MA/pX -- -- SSLY/PALT -- -- -- -- 
X/CA -- -- SQAF/PLRA -- -- -- -- 
CA/NC TKVL/VVQP PAIL/VHTP SKLL/ATVV AAAM/SSIA -- KMQL/LAEL -- 
CA/pX -- -- -- -- ARVL/AEAM -- KMML/LAKA 
pX/NC -- -- -- -- ATIM/MQRG -- AKAL/QTGL 
NC/pX -- -- -- -- RQAN/FLGK -- -- 
Gag/PR ASIL/PVIP LECL/LSIP TSLL/TLDD PAVS/LAMT SFNF/PQIT GFVN/YNKV QFVG/VTYN 
PR/Pol PVIL/PIQA PMVG/VLDA LQVL/TLNL  LTNL/IGRA TLNF/PISP RLVM/AIQS KLVL/AQLS 
TF1/RT PAVL/GLEH -- -- -- -- -- -- 
RT-RH/IN VLQL/SPAD unk unk FQAY/PLRE RKIL/FLDG CQTM/MIIE TGVF/WVEN 
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In HTLV-I protease, the S4 and S4’ subsites are shallow, surface exposed 
pockets. In the natural substrates, the P4 and P4’ positions are typically hydrophobic 
residues, with proline being the most prevalent.  A variety of substrates are tolerated, 
which includes polar residues such as serine and threonine and charged residues such 
as aspartic acid and histidine.  
 Unlike the S4 and S4’ subsites, the S3 and S3’ pockets are large and can 
accommodate a wide variety of side chains. The natural substrate of CA/NC has a lysine 
residue in the P3 position. However, a hydrophobic residue such as phenylalanine, 
leucine, or valine in this position is catalyzed with nearly the same efficiency. The S2 and 
S2’ subsites are also large and are particularly inhabited by the β-branched residues of 
valine and isoleucine. The S1 subsite in HTLV-I protease is occupied by a P1 leucine. In 
this site, a P1 β-branched amino acid is not tolerated. The S1’ typically is occupied by a 
P1’ proline. Therefore, the most common scissile site (P1/P1’) is Leu/Pro. Table 3.3 








Table 3.3 HTLV-I Protease Cleavage of Natural Substrates. 
 










As can be seen in Table 3.3, all the P1 residues are leucine. The P1’ residues 
are mostly proline with the exception of a P1’ valine in the CA/NC substrate, a recently 
reported P1’ glycine in the TFP/RT substrate (Heidecker et al., 2002), and an unusual 
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HTVL-I PROTEASE C-TERMINAL CLEAVAGE 
 
 
4.1 HTLV-I C-Terminal Cleavage Junction 
 
 
 As can be seen in the sequence alignment in Figure 4.1, HTLV-I protease has an 
extended C-terminal “tail” that is not common to other retroviral proteases with the 
exception of other leukemia viral proteases (Shuker et al., 2003). 
 
 
HTLV-I  ---IGRDALQQCQGVLYLPEAKGPPVIL 
HTLV-II ---IGRDALQQCQGLLYLPDDPSPHQLL 
BLV     ---IGRDVLSRLQASISIPEEVRPPMVG 
MuLV    L--LGRDLLTKLKAQIHFEGSGAQVVGPKGQPLQVL 
RSV     ---LGRDCLQGLGLRLTNL--------- 
HIV-1   ---IGRNLLTQIGCTLNF---------- 
HIV-2   ---FGRNILTALGMSLNL---------- 
SIV     ---FGRNLLTALGMSLNL---------- 
 
Figure 4.1  Sequence alignment of C-terminal regions of several retroviral proteases.  
BLV, bovine leukemia virus; MuLV, murine leukemia virus; RSV, Rous sarcoma virus; 
HIV, human immunodeficiency virus 1 and 2; SIV, simian immunodeficiency virus. 




Within this tail domain, there is a potential cleavage site between residues 
Leu115-Pro116 at the N-terminus of the last 10 amino acids (Figure 4.1), with a 
corresponding cleavage site in HTLV-II. 
Several natural amino acid sequences recognized by HTLV-I protease have 
been reported (Kobayashi et al., 1991; Heidecker et al., 2002; Mariani & Shuker, 2003; 
Shuker et al., 2003); these are shown again in Table 4.1. All of these sequences contain 




Table 4.1 HTLV-I Protease Cleavage of its Natural HTLV-I Substrates (see also 
Figure 2.6). 
 











  As there is no tail in the RSV protein on which the theoretical structure is based, 
it may be expected that the modeling results would produce an open, random coil 
structure for the tail as is shown in Figure 4.2(b). For comparison, HIV-1, which like RSV 
protease also has no tail, is shown in Figure 4.2(a). Whether or not this tail is important 
in the function of the protease is still uncertain.  
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(a)  (b)  
 
Figure 4.2  (a) Crystal structure of HIV protease (PDB 1D4L); (b) theoretical model of      
HTLV-I protease (PDB 1O0J). 
 
 
A mutant of bovine leukemia virus (BLV) protease that does not contain its ten C-
terminal residues was prepared by Précigoux and co-workers, and it correctly processes 
a peptide corresponding to the BLV MA/CA cleavage junction (Précigoux et al., 1993). 
On the other hand, it has been reported that the last ten C-terminal residues of HTLV-I 
protease are required for activity (Hayakawa et al., 1992). However, this was based on 
detection of unprocessed Gag during expression of deletion mutants, which were not 
purified or tested further (Herger et al., 2004) Victoria Mariani and Bryan Herger 
engineered and expressed a construct of HTLV-I protease (L40I) to prevent 
autoproteolysis based on work by Louis and co-workers and a construct (L40I ∆10) 
without the last ten C-terminal residues. In agreement with Précigoux’s results for BLV, it 
was demonstrated that the truncated HTLV-I protease cleaves the HTLV-I MA/CA 








L40I 590 ± 50 




Since enzymatic activity appears to be unaffected by the “C-tail” region,  
investigation as to why this C-terminal tail is not cleaved when there is a natural Leu-Pro 
scissile site could be significant in understanding HTLV-I protease enzymology.  
Residues 114-117 are YLPE, sequentially. The common native pattern spanning the 
cleavage junction, P2 through P2', is to have a P2 valine or isoleucine; a P1 leucine; a 
P1' proline, valine, serine, or glycine; and a P2' valine or isoleucine. It is conceivable that 
point mutations led to the modification of one or both residues, resulting in a shift of the 
site further downstream in the TFP fragment. We hypothesized that the site was 
inhibited by either the steric effects of the P2 tyrosine or by the electronic effects of the 






4.2 C-Terminal Tail Cleavage Junctions 
 
 
Steric hindrance plays a significant role in HTLV-I protease’s affinity for 
substrate, as demonstrated by the work of Louis and co-workers to analyze a second LP 
site (Leu40-Pro41) in HTLV-I protease. They report that mutating Leu40 to isoleucine 
eliminates autoproteolysis (Louis et al., 1999).  Isoleucine differs from leucine only in the 
placement of the branch on the side chain.  Further, the list of known substrates shows a 
clear preference for a small, aliphatic residue in the P2 position. The Leu115-Pro116 
junction, shown in Figure 4.1, is a putative cleavage site; however, as previously noted, 
this particular site is not cleaved during proteolytic processing of the protease.  
In order to determine whether the C-terminal region is inhibited by steric 
interference of the P2 Tyr114 or the electronic effects of the charged P2' Glu117, we 
incubated the wild-type HTLV-I protease with synthetic peptides bearing mutations in the 
P2, P2', and both substrate positions. The peptides VLVLPEAKGP, VLYLPEAKGP, and 
VLVLPVAK correspond to Y114V, E117V, and a double mutant with both Y114V and 
E117V, respectively. We also incubated a synthetic wild-type substrate (VLYLPEAKGP) 
with the protease. Cleavage products were analyzed by LC-MS. As expected, the wild-
type substrate was not cleaved by the protease (data not shown). The LC-MS data for 
the VLVYLPEAKGP (Y114V) peptide (Figure 4.3) reveal only the parent ions at 1022.7 
Da (1022.2 predicted) indicating that the Y114V mutant is not cleaved and Tyr114 does 














Figure 4.3 LC-MS spectrum of HTLV-I protease cleavage of VLVLPEAKGP (Y114V) peptide. 
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The data from the VLYLPEAKGP (E117V) peptide (Figures 4.4 and 4.5) and the 
double mutant, VLVLPVAK, (Figure 4.6) exhibit cleavage products. A very low level of 
cleavage is observed between the P3 leucine and P2 tyrosine in the E117V mutant with 
the presence of the peak at 844.3 Da (844.0 predicted) corresponding to the NH2-
YLPVAK-OH cleavage product (Figures 4.4 and 4.5). The double mutant shows a more 
significant level of cleavage, and is cut between the P3 leucine and P2 valine as 
indicated by the presence of the peak at 626.6 Da (625.8 predicted) corresponding to 
the NH2-VLPVAK cleavage product (Figure 4.6). However, neither substrate was cut at 























Figure 4.4  LC-MS spectrum of HTLV-I protease cleavage of VLYLPVAKGP (E117V) peptide cleavage.









































Figure 4.5 Enlarged LC-MS spectrum of HTLV-I protease cleavage of VLYLPVAKGP (E117V) peptide cleavage.
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Figure 4.6  LC-MS spectrum of HTLV-I protease cleavage of VLVLPVAK (double mutant) peptide.
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To rule out the size of the substrates as a contributing factor to the unusual 
cleavage pattern, we prepared an extended double mutant:  
Ac-QGVLVLPVAK-HMBA- ( = peptide linked to bead). This peptide was incubated 
with HTLV-I protease while attached to the bead and then analyzed by LC-MS. The 
results in Figure 4.7 show a peak at 456.3 Da corresponding to Ac-QGVL-OH 
(calculated mass: 457.4). Once again, the substrate was not cut between the P1 leucine 





























Figure 4.7  LC-MS spectrum of HTLV-I protease cleavage of Ac-QGVLVLPVAK-HMBA- (double mutant) peptide. 
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Two site-directed mutants of HTLV-I protease (Y114V and E117V) were prepared by 
Bryan Herger from the L40I mutant to confirm the results obtained from the synthetic 
peptides. The two new mutants along with L40I, L40I ∆10, and wild-type (wt) protease 
were analyzed by SDS-PAGE (Figure 4.8). The E117V mutant (Lane 5) has an 
additional band below the intact protein band that is not present in the wt (Lane 3) or 
Y114V (Lane 4), indicating that E117V has an additional shorter fragment than the wild-
type or Y114V proteases. Lane 6 is a mixture of 50% E117V and 50% Y114V and shows 
the same band as in the E117V. Lane 1 is the deletion mutant, L40I ∆10. This band 
should be approximately equal in size to a mutant cleaved at position 114 or 117. Lane 2 
is L40I with no autoprocessing. This demonstrates that the C-terminal “tail” domain has 
undergone autoproteolysis and that it is the Glu117 that hinders cleavage of the C-





  L          1           2          3          4         5          6 
 
Figure 4.8  Electrophoresis Gel showing bands from HTLV-I wt and mutants (Lane 
1: L40I ∆10; Lane 2: L40I; Lane 3: wt; Lane 4: Y114V; Lane 5: E117V; and Lane 6: 
mixture of Y114V and E117V; L = DNA marker). 
 
 
To verify the SDS-PAGE result, the mutant cleavage products were analyzed by 
MALDI (Figures 4.9 and 4.10). The full-length His-PR sequence was at the expected 
mass (m/z =15644.8 for the E117V mutant and m/z = 15637.9 for the Y114V mutant). 
For the E117V mutant (Figure 4.9), an additional peak corresponding to the expected 
mass of the C-terminal cleavage sequence (m/z = 14051.8) demonstrated that cleavage 
did occur. However, this cleavage is not at the Leu115-Pro116 scissile site. Instead, it is 
shifted two amino acids upstream, which is in agreement with our synthetic peptide 
mutants. There is no C-tail cleavage for the Y114V mutant (Figure 4.10). However, an 
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interesting cleavage was observed at around 10 kDa. This peak appears to be another 
processing site at Leu78-Pro79.  The Leu72-Pro73 has no cleavage because of the 
presence a serine residue in the P2 site, which is not tolerated for cleavage. MALDI 
spectra confirm the autoprocessing site at Leu78-Pro79, where the N-terminal sequence 
corresponds to the expected mass (m/z = 10277.3) in both the E117V and Y114V 









Figure 4.9 MALDI spectrum of E117V. The a peak at m/z = 10277 Da (Expected 
10244 Da) corresponding to the N-terminal PR(1-78) Leu78-Pro79 cleavage 
fragment and the C-terminal PR(79-115) cleavage fragment at m/z = 5422.7 Da. 
 
 





Figure 4.10 MALDI spectrum of Y1147V. The peak at m/z = 10256.4 Da (Expected 
10244 Da) corresponding to the N-terminal PR(1-78) Leu78-Pro79 cleavage 







As previously noted, Louis et al. concluded that steric considerations play a 
significant role in HTLV-I protease’s affinity for substrate by demonstrating prevention of 
normal autoproteolysis in a L40I mutant. Isoleucine differs from leucine only in the 
placement of the methyl branch on the side chain.  Further, the list of known substrates 
NH2-PR(1-78) 
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shows a clear preference for a small, aliphatic residue in the P2 position. The peptide 
having a single mutantion of tyrosine to valine did not show any cleavage products, 
indicating that the tyrosine alone does not inhibit protease cleavage. The glutamic acid 
to valine mutation showed only a slight cleavage between the VL and YLPVAKGP, 
which is not at the typically favored L/P scissile junction. Having a tyrosine to valine 
mutation along with a glutamic acid to valine mutation in the double mutant leads to a 
much more prominent cleavage site, showing a more favorable proteolysis to occur at 
the next site in the nonfunctional TFP peptide domain. The double mutant shows this 
different cleavage junction between Val114 and Leu115. This suggests that charged 
species in the P2’ site have electronic interactions that inhibit proteolytic cleavage and 
may play a role in the positioning the substrate into the active site, which may explain 
why the substrate is not cleaved at the normally favored L/P junction.  
 Structure determination of HTLV-I protease has been an important goal toward 
understanding the enzymology of the protease. However, structure determination by 
NMR and x-ray crystallography has been unsuccessful. The L40I mutation that prevents 
autoprocessing at this site was hoped to have been a key toward forming protease 
dimers at concentrations large enough for NMR determination. It appears from the 
MALDI spectra reported here that an additional mutation, L78I, may provide the 
necessary stability for sufficient dimerization. Further cleavage studies need to be 
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 Detailed X-ray crystallography has revealed much regarding the inhibitor binding 
and catalysis of aspartic acid proteases. Inhibitors that mimic the tetrahedral 
intermediate have been shown to have a high affinity for binding to the active site. In the 
protease-inhibitor complex, the catalytic aspartic acids lie near the scissile bond between 
the P1 and P1’ positions and the carbonyl group of the glycine in the Asp-Thr-Gly 
catalytic triad forms a hydrogen bond with the amino group of the inhibitor at positions 




Figure 5.1 HIV-1 protease (PDB 7HVP) with inhibitor JG-365 (shown as sticks; cpk 
format) bound in the acitive site. The catalytic triads (Asp-Thr-Gly) are also shown as 












5.2 Statine-, 4-Amino-3-hydroxy-5-phenylpentanoi acid-, and Hydroxyethylamine-






   Kinetic results for several HIV and pepsin protease inhibitors assayed with HIV 
and HTLV-I proteases have been reported (Daenke et al., 1994, Louis et al., 1999, 
Teyura et al., 2002). Table 5.1 gives the Ki data for inhibitors that were assayed with 
HTLV-I protease. Based on this data, the best inhibitor was found to be the HIV-1 
inhibitor: JG-365 (Ac-Ser-Leu-Asn-Phe-CH(OH)CH2NH-Pro-Ile-Val-OMe) with Ki = 7.2 
nM (Ding et al., 1998). However, as reported by Julie Ha, these data may not have been 




Table 5.1  Ki values for compounds that have been tested for inhibition of HTLV-I 
protease. 
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 >10 0.0004 (Louis et 
al., 1999) 
N-1270 Arg-Val-Leu*-Phe-Glu-Ala-Nle-NH2
b 127 0.05 (Teruya et 
al., 2002) 
N-1465 Ac-Thr-Ile-Nle*-Nle-Gln-Argb 12.7 0.78 (Teruya et 
al., 2002) 
N-1460  Ser-Gln-Asn-Phe*-Pro-Ile-Val-Glnb 7.3 1 (Teruya et 
al., 2002) 
1 Boc-Val-Val-Phe(PC)Phe-Val-Val-NH2
a 0.08 0.0004 (Louis et 
al., 1999) 




2 Lys-Thr-Lys-Val-Sta-Val-Gln-Pro-Lys   >10    >10 (Louis et 
al., 1999) 
3 Pro-Pro-Cys-Val-Phe-Sta-Ala-Met-Thr-Met   >10 NDc (Louis et 
al., 1999) 
4 Pro-Tyr-Val-Phe-Sta-Ala-Met-Thr   >10 12.5 (Louis et 
al., 1999) 
5 Ala-Pro-Gln-Val-Sta-Val-Met-His-Pro 0.05 0.13 (Louis et 
al., 1999) 
6 Ac-Pro-Gln-Ile-Thr-Leu-Trp-Gln-Arg-Pro-NH2 1700 IC50 > 2000 (Daenke et 
al., 1994) 
7 Ac-Thr-Leu-Asn-Phe 252 IC50 = 1500 (Daenke et 
al., 1994) 
8 Ac-Thr-Val-Ser-Phe-Asn-Phe 217 6.1 (Daenke et 
al., 1994) 
N-1395 Ac-Leu-Val-Phe-H 93 IC50 = 0.90 (Teruya et 
al., 2002) 
9 Pro-Val-Ile-Pro-Leu-Asp-Pro-Ala-Arg-Arg-Pro-Val 87.2 17.1 (Daenke et 
al., 1994) 
10 Gln-Met-Gln-Gly-Val-Leu-Tyr-Leu 70 IC50 > 400 (Daenke et 
al., 1994) 




12 Tyr-Leu-Pro-Glu-Ala-Lys-Arg-Pro-Pro-Val-Ile-Leu 5.7 84 (Daenke et 
al., 1994)  
a Asterisk denotes a reduced peptide bond, b PC denotes replacement of the amide bond with –P(O)(OH)-, 
and c ND = not determined. 
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In addition to compounds tested in Table 5.1, five other peptidomimetic pepsin 
inhibitors containing a statine isostere have also been tested against HTLV-I protease 
(Ding et al., 1998). Table 5.2 shows the inhibition activity of these five inhibitors. The CS-
I-25 (Iva-Lys-Val-Sta-Ala-Iaa) inhibitor was found to be a reasonable inhibitor with a Ki = 
7.2 ± 0.2 nM (10 nM with PR-His-tag present). However, as with the JG-365, the CS-I-25 
was probably improperly corrected for protease concentration (Ha et al. 2002). 
 
 
Table 5.2 Inhibition of HTLV-I Protease by Pepsin Inhibitors. 
Inhibitor Structurea Ki (pepsin)b 
(nM) 
Ki (HTLV-I PR) 
(nM) 
CS-I-51 Iva-Val-Val-Sta-Lys-Iaa 0.72 466 ±  74 
CS-I-22 Iva-Val-Nle-Sta-Ala-Iaa 0.030 138 ±  10 
CS-I-25 Iva-Lys-Val-Sta-Ala-Iaa 19.2 7.2 ±  0.2 
CS-I-27 Boc-Lys-Val-Val-Sta-Ala-Iaa 0.22 142 ±  6 
CS-I-52 Iva-Val-Val-Sta-Ala-Lys-OMe 0.10 7.200 ±  1.500 
a Iva, isoveryl (CH3)2CHCH2CO; Nle, norleucine CH3(CH2)3CH(NH2)COOH; Sta 
(3S,4S)-statine (CH3)2CHCH2(NH2)CH(OH)CH2COOH; Iaa, isoamylamine 




Statine, 4-amino-3-hydroxy-5-phenylpentanoic acid (AHPPA), and phenyl-
hydroxyethylamine (F-HEA) were expected to be potent inhibitors of HTLV-I protease 
based on previous work reported by Ding et al. Akaji et al. tested several HEA inhibitors 
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against HTLV-I protease, in which the best inhibitor resulted in a Ki = 38 ± 8 nM (Akaji et 
al., 2003). The JG-365 has a 10-fold increase in potency over the Akaji et al. HEA 
inhibitor. However, as previously stated this may have been miscalculated (Ha et al. 
2002).  
Statine, AHPPA, and HEA are nonstandard amino acids that mimic the 
tetrahedral intermediate of aspartic acid protease catalyzed hydrolysis of the peptide 
substrate.  These structures are illustrated below in Figure 5.2, which shows statine, 
























The statine and AHPPA peptides are easily synthesized by solid-phase methods. 
The statine iso-butyl side chain is expected to bind in the S1 pocket normally occupied 
by a P1 leucine in the natural substrates. Statine and AHPPA are also expected to have 
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tight S1 binding. Little is known about the structure-activity relationships (SAR) at each 
position in HTLV-I protease. A small library of nine peptides were synthesized to 
investigate the inhibition potency of peptide mimetics, which will lead to the development 
of potent nonpeptide inhibitors. 
  







Where Ac = acetyl, X (P3), Y (P2), and Z (P2’) are various amino acids with their 
corresponding position, R = NH2Et, OMe, or OH. Peptides corresponding to the MA/CA, 
TF1/PR, and PR/TFP cleavage junctions were prepared (Table 5.3).  
 
 
Table 5.3 HTLV-I Cleavage Junctions for Peptide Mimetics. 








The X (P3) contains Qln, Ser, or Val; the Y(P2) and Z(P2’) consists of Val or Ile; all P1’ 
are Pro; and the P1 site have statine, AHPPA, or F-HEA. The statine- and AHPPA-
based peptide structures are shown in Figure 5.3. 
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3    VI-Sta-PI
4    QV-AHPPA-PV
5    SI-AHPPA-PV

































































Figure 5.3 Structures of statine and AHPPA inhibitors corresponding to MA/CA, TF1/PR, 
and PR/TFP cleavage junctions. R = NH2Et, OMe, or OH. 
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The statine- and AHPPA-based peptides were first synthesized on solid support 
using Argopore amine-substituted beads (Wellings & Atherton, 1997). To each bead, 4-
hydroxymethylbenzoic acid (HMBA) was attached as a cleavable linker by base-
catalysis with diisopropylethylamine (DIPEA). Then the first 9-fluorenylmethoxycarbonyl 
(Fmoc)-protected amino acid was attached to the linker by forming the symmetrical 
anhydride with N,N’-dicyclohexylcarbodiamide (DCC) and adding this to the HMBA-
linked bead with 4-dimethylaminopyridine (DMAP). The Fmoc was deprotected with 20% 
piperdine (mechanism shown in Figure 5.4). Following deprotection, the next amino acid 
was added by base catalysis with DIPEA and a coupling agent---2-(1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) for primary amino acids and 2-
(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) for 














20 % piperidine, DMF









The iterative process of addition and deprotection was repeated until the final 
desired amino acid sequence was completed. This process is shown in the general 















































Figure 5.5 General scheme of solid-phase synthesis. 
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The yields were extremely poor so another route was attempted. In the second 
round of peptide synthesis, pre-loaded Val(Ile)-Tenta-Gel beads were used instead of 
the amine substituted Argopore beads. The only deviations from the synthesis from the 
previous method were that equal molar amounts of HOBt and TBTU were used in each 
addition step and TFA was used to cleave the peptide from the bead.  This gave much 








 Similar to the statine- and AHPPA-based inhibitors, the F-HEA-based inhibitors 
also mimic the MA/CA, TF1/PR, and PR/TFP cleavage junctions. The structures for 























































7   QV-F-HEA-PV
8   SI-F-HEA-PV
9   VI-F-HEA-PI  
Figure 5.6 Structures of Phe-HEA inhibitors corresponding to MA/CA, TF1/PR, and 
PR/TFP cleavage junctions. 
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The HEA synthesis followed a two-part strategy (Figure 5.7). The first step 
followed standard Fmoc solid-phase chemistry on an amine-substituted Argopore bead 
with the cleavable HMBA linker. The second step involved attaching N-Tosyl-L-
phenylalanine chloromethyl ketone (TPCK), which contains the starting block for Phe-
HEA. As shown in scheme in Figure 5.8, the ketone of the TPCK was first protected as 
an acetal and then attached to either Pro-Val-HMBA- or Pro-Ile-HMBA- following a 
similar strategy by Daniel Rich et al. (Rich et al., 1992). Next, the Tosyl protecting group 
was removed by an electron transfer reaction with NaBH4, hν, and 2,7-
dimethoxynapthalene as an electron donor (Hamada et al., 1986). Once it was 
deprotected, the final two amino acids were added to the HEA centerpiece via Fmoc 
synthesis.  
 




NaI  2 eq 
NaHCO3 2.5 








































Before the TPCK could be added to the beads containing either Pro-Val or Pro-Ile, the 
reaction status was checked. TPCK (10) was added to proline following a similar 
procedure outlined in the scheme in Figure 5.8 to synthesize compound 11. The reaction 
shown in Figure 5.8 was completed with 2 equivalents of proline rather than reacted with 














NaI  2 eq 
NaHCO3 2.5 eq 
DIPEA 5 eq  
DMF
 




 Comfirmatiion of compound 13 was verified by 1H NMR (see experimental 
section Chapter 9). There was an upfield shift in the methylene protons of 10 from δ 4.25 
to overlapping the β protons at δ 3.42. In addition the presence of the praline hydroxyl 






5.5 Fluorescence Assays of Synthetic Peptide Inhibitors 
 
 
Following cleavage with ethylamine, the statine and AHPPA peptides were 
washed and purified by HPLC. The purity was confirmed by LC/MS. Inhibition by the 
synthesized peptide mimetics was assayed by fluorescence resonance energy transfer 
(FRET) with a CA/NC fluorogenic substrate: 4-(4-Dimethylaminophenylazo)benzoyl-γ-
aminobutyric acid-PQVLPVMH-5-(2-aminoethylamino)-1-napthalenesulfonic acid 
(Dabcyl-GABA-PQVLPVMH-EDANS). On this substrate, EDANS serves as the 








































Figure 5.9  Fluorogenic substrate (Dabcyl-GABA-TKVLVVQP-EDANS) for HTLV-I 
protease.  This substrate is based on the CA/NC junction, TKVLVVQP (green), with 
fluorophore EDANS in yellow, and quencher Dabcyl in violet. 
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When the peptide is cleaved, EDANS is no longer quenched by Dabcyl. The 
inhibition constants of each inhibitor can then be measured by monitoring the amount of 
fluorescence present by the substrate. One of the inhibitors with the highest percent 
inhibition (QV-Sta-PV) and QV-AHPPA were taken to the CDC for in vitro analysis on 
HTLV-I infected cell lines. 
 
 
5.6 Preliminary Fluorescence Results 
 
 
 The FRET assay was used to determine the percent of inhibition of the statine 
and AHPPA inhibitors.  In this assay, the inhibition of crude unpurified peptides were 
measured against HTLV-I substrate. The percent inhibition was based on native 
substrate cleavage set to 0%. The relative inhibition of the peptides were then measured 










Inhibitor Percent Inhibition 
 No inhibitor present      0% 
MA/CA Ac-Q-V-Sta-PV   87.6% 
TF1/PR Ac-S-I-Sta-PV   63.1% 
PR/TFP Ac-V-I-Sta-PI   34.5% 
MA/CA Ac-Q-V-AHPPA-PV   61.6% 
TF1/PR Ac-S-I-AHPPA-PV   41.9% 
PR/TFP Ac-V-I-AHPPA-PI   42.7% 
MA/CA Ac-QV-F-HEA-PV   46.5% 
TF1/PR Ac-SI-F-HEA-PV   31.5% 
PR/TFP Ac-VI-F-HEA-PI   67.3% 
CS-I-25 Iva-KV-Sta-A-Iaa   86.4% 
 
 
 These data indicate that the statine MA/CA inhibitor had the best competitive 
inhibition with a result of only 12% cleavage of the native substrate. This is comparable 
to the CS-I-25 pepsin inhibitor, which showed 14% cleavage of the substrate. The 





5.7 Inhibition Constants of Purified Peptides 
 
 
 The Ki values for purified inhibitors were determined by measuring inhibitor 
activity at concentrations in the range of 1 to 5 µM against varying substrate 
concentrations of 5 to 20 µM. Measurements were taken by monitoring the fluorescence 
of the Dabcyl-GABA-PQVLPVMH-EDANS substrate. The Ki values were then 
determined by a method described by Dixon (Segel, 1975).  The Ki was also determined 




























Figure 5.10 Dixon plot for Ac-QV-Sta-PV inhibitor. 
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Table 5.5 Ki’s of the Inhibitors of HTLV-I Protease. 
Inhibitor Ki (His-Pr) 
(nM) 
 
Ac-QV-Sta-PV 29 ± 4 
Ac-SI-AHPPA-PV 38 ± 6 
CS-I-25 30 ± 3 
  
   As can be seen in Table 5.5 the MA/CA Ac-QV-Sta-PV (Ki = 29 ± 4 nM) has the 
same inhibition constant as the CS-I-25 pepsin inhibitor (Ki = 30 ± 3 nM). The previously 
reported 10 nM inhibition for the CS-I-25 by Ding et al. is on the same order of 
magnitude as the 30 nM reported in this work. In addition, Louis et al., also assayed a 
HTLV-I protease MA/CA statine-based inhibitor (APQV-Sta-PVMHP). This peptide (Ki = 
50 nM) had both the P1 Leu and P1’ Pro replaced with statine while the Shuker MA/CA 
inhibitor only had the P1 Leu replaced with statine. The Shuker inhibitor yielded slightly 
better inhibition. The similarity in inhibition of the MA/CA statine inhibitor and CS-I-25 
was also shown with the percent inhibition assay shown in Table 5.4. Akaji et al 
described synthesis of a hydroxyethylamine isostere that gave a Ki = 38 ± 8 nM when 
assayed against HTLV-I protease (Akaji, 2003).  
It was expected that the inhibitors synthesized would show Ki’s of less than 1 nM 
based on work by Rich et al. on HIV protease inhibitors. Unfortunately, none of the 




5.8 Inhibition of HTLV-I Protease in Cell Culture 
 
 
Synthesized peptides with good in vitro activity were tested in two different cell-
based assays. It has been previously shown that HTLV-I can be passed from irradiated 
virus-producing cell lines such as MT-2 and HUT-102 by co-culture with uninfected 
peripheral blood mononuclear cells (PBMCs) (Kitamura et al., 1993; Lal & Heniene, 
1996). This assay was used to determine if the inhibitors prevent the spread of HTLV-I. 
The effectiveness of the protease inhibitors was ascertained by monitoring culture 




5.9 Results of Inhibition of HTLV-I Protease in Cell Culture 
 
 
 The PBMC co-cultured with irradiated HUT-102 HTLV-I infected cell lines were 
treated biweekly with 5, 10, and 20 µM concentrations of the Ac-QV-Sta-PV, CS-I-25, 
and a nonbonding peptide, Leu-Leu-Leu (L3). In addition, a HUT-102 cell line (no co-
culture) was also treated biweekly with the same concentrations of inhibitors. The co-
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cultured irradiated HUT-102s and PBMCs were assayed by p19 antigen ELISA. The 
results of the ELISA are shown in Figure 5.14. 
 



































Figure 5.14   Results of p19 ELISA following five weeks of treatment.  
 
As can be seen in Figure 5.14, this five-week treatment is beginning to show 
signs of inhibition of protease inhibitors in an in vitro cell culture assay. The QV-Sta-PV 
and QV-AHPPA-PV show inhibition at 5 and 10 µM compared to the control peptide L3 
(5, 10, and 20 µM). The L3 controls are all show p19 antigen near the range of cells that 
were not treated with any inhibitor. It is unclear why inhibitors at 20 µM are also in the 
same range as cells not treated and cells treated with the control. However, some of the 






The MA/CA statine inhibitor has thus far shown the highest competitive inhibition 
based on fluorescence results with crude and purified compounds. The percent inhibition 
was found to be 88% compared to a previously reported CS-I-25 pepsin inhibitor, which 
had an 86% percent inhibition. The Ki for the MA/CA statine inhibitor was found to be 29 
± 4 nM, which is also close to the Ki = 30 ± 3 nM for CS-I-25. It was hoped that the 
statine, AHPPA, and HEA inhibitors would give better inhibition. One of the difficulties 
with HTLV-I protease inhibitor assays is that the protease is not well behaved in solution 
and the activity is low compared to other retroviral proteases. This may be a benefit to 
people who are infected with HTLV-I or are at risk for HTLV-I infection. If the protease 
were more active, the prevalence of HTLV-I infection and transmission might be much 
greater than the 15-20 million people infected that current statistics report. 
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6.1.1 Mutation of HTLV-I Protease to Recognize an HIV-1 Substrate 
 
 
 Accurate alignment of retroviral proteases is difficult due to low sequence 
homology, especially since the structure of HTLV-I protease is unknown. In addition to 
our models, in previous work, Tözsér and others developed a theoretical model in order 
to determine which residues were significant for activity (Tözsér et al., 2000). A particular 
method for testing alignment accuracy is to mutate residues of the unknown protein 
aligned with that of a known structure and test for specificity. Wu et al. used this strategy 
to mutate RSV protease residues to match those of HIV-1 protease (Wu et al., 1998). 
Employing that same strategy, Bryan Herger mutated HTLV-I protease to match putative 
active site residues in HIV-1. The alignments of RSV and HIV-1 protease along with 
three HTLV-I alignments are shown in Figure 6.1. The three HTLV-I aligments are: 
Tözsér’s (T), our previously published alignment (S1), and our revised alignment (S2). 
The RSV wt residues highlighted in yellow indicate those that were mutated by Wu et al. 
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HTLV-T  PVIPLDPARRPVIKAQVDTQT-----S-HPKTIEALLDTGADMTVLPIALFSS-NT-P-L-KN-T--SVLGA 
HTLV-S1 PVIPLDPARRPVIKAQVDTQT---S-HP--KTIEALLDTGADMTVLPIALFSSN-----TP-LK--N-TSVL 
HTLV-S2 PVIPLDPARRPVIKAQVDTQT---S-HP--KTIEALLDTGADMTVLPIALFSSN-----TP-LKN-TSVLGA 
RSVwt   LAMTMEHKDRPLVRVILTNTGSHPVKQ-RSVYITALLDSGADITIISEEDWPT-DW-P-V-MEAANPQIHGI 
HIV-1   PQITLW--KRPLVTIKIG-----------GQLKEALLDTGADDTVIEE--MS---LPGRW-KPK---MIGGI 
 
HTLV-T  GGQTQDHFK-LTSLPVLIRLPFRTTPIVLTSCLVDTKNNWA--IIGRDALQQCQGVLYLPEAKGPPVIL 
HTLV-S1 GAGGQTQDHFK-LTSLPVLIRLPFRTTPIVLTSCLVDTKNNWAIIGRDALQQCQGVLYLPEAKGPPVIL 
HTLV-S2 GGQTQDHFK-LTSLPVLIR--LPFRTTPIVLTSCLVDTKNNWAIIGRDALQQCQGVLYLPEAKGPPVIL 
RSVwt   GGGIPMRKSRD-MIELGVINRDGSLERPLLLFPAVAMVRGS--ILGRDCLQGLGLRLTNL--------- 
HIV-1   GGFIKV-RQY-DQIIIEIC-----GH-KAIGTVLVGPTPVN--IIGRNLLTQIGCTLNF---------- 
 
Figure 6.1 Multiple alignment of RSV protease (RSVwt), HTLV-I protease (Shuker 
alignment: S), HTLV-I protease (Tozser alignment: T), HIV-1 protease.  Residues in 







The mutations based on these alignments are shown in Figure 6.2(a,b,c). The 
mutations based on the Tözsér alignment were: M37D, D65V, V92L, N96T, N97P, 
W98V, and A99N. The mutations based on the S1 alignment were: M37D, T63V, C90L, 
K95P, and N96V. The mutations based on the S2 alignment were: M37D, D65V, C90L, 



















                           D                           
PVIPLDPARRPVIKAQVDTQTSHPKTIEALLDTGADMTVLPIALFSSNTPLKNTSVLGAGGQTQ 
DHFKLTSLPVLIRLPFRTTPIVLTSCLVDTKNNWAIIGRDALQQCQGVLYLPEAKGPPVIL  
V                       L   TPVN  
 
(b) 
                           D                         V 
PVIPLDPARRPVIKAQVDTQTSHPKTIEALLDTGADMTVLPIALFSSNTPLKNTSVLGAGGQTQ 
DHFKLTSLPVLIRLPFRTTPIVLTSCLVDTKNNWAIIGRDALQQCQGVLYLPEAKGPPVIL  
                         L    PV  
 
(c) 
                                    D 
PVIPLDPARRPVIKAQVDTQTSHPKTIEALLDTGADMTVLPIALFSSNTPLKNTSVLGAGGQTQ 
DHFKLTSLPVLIRLPFRTTPIVLTSCLVDTKNNWAIIGRDALQQCQGVLYLPEAKGPPVIL  
V                        L    PV 
 
Figure 6.2  HTLV-I protease mutations made based on different alignments. Target 
residues are bold with mutations above or below the parent sequence. (a) mutations 
based on Tözsér (T) alignment; (b) Mutations based on Shuker alignment S1; (c) 




6.1.2  Kinetic Assays of HTLV-I Protease Mutants 
 
 
 For the kinetic assays of HTLV-I mutant constructs, Bryan Herger used an HIV-1 
substrate (H-5910) to measure cleavage based changes in absorbance (Toth & 













Table 6.1  Summary of kinetic data for the various protease mutants. 
Mutant kcat (s-1) KM (µM) kcat/KM (mM
-1 s-1) 
HIV-1 protease 
(Toth & Marshall, 
1990) 




3.6x10-3 ± 2.9x10-4 64 ± 10 0.056 ± 0.0045 
HTLV-I protease: 
Shuker mutant (S1) 1.6x10
-3 ± 1.3x10-4 52 ± 8 0.031 ± 0.0025 
HTLV-I protease: 
Tözsér mutant (T) 4.5x10
-4 ± 4.4x10-5 39 ± 8 0.012 ± 0.0011 
HTLV-I protease: 




The mutant based on Tözsér's alignment was shown to have a catalytic 
efficiency, kcat/KM, of 0.012 mM-1 s-1, while the mutant based on Shuker's alignment gave 
a kcat/KM of 0.031 mM-1 s-1. The S2 mutant, which had two mutations from Tözsér’s 
alignment and two from S1 had a kcat/KM of 0.056 mM-1 s-1, indicating that Asp65 plays a 
more significant role in binding substrate. These data indicate that the revised S2 
alignment better correlates active site residues in HIV-1 and HTLV-I proteases. 
Therefore, the theoretical model based on this alignment is more likely to reflect the 
actual structure of HTLV-I protease based on similarity to HIV-1 protease. The second 
theoretical model was deposited in the protein data bank based on this revised 
alignment. This model is shown in Figure 6.3 (Herger et al., 2004).  Figure 6.4 shows the 
two theoretical models, PDB 1O0J and PDB 1TP1, superimposed.  The superimposed 
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illustration shows that there are marked differences in the two structures, especially in 


















6.2  Location of Tryptophan Residues in HTLV-I Protease Theoretical Models 
  
 
 Unlike other retroviral proteases, HTLV-I protease contains a tryptophan residue 
at position 98 in each dimer. This position is in proximity to residues Ile100-Ile101-Gly102, 
which are in the active site. However, without a known structure it is difficult to determine 
where those two tryptophan residues lie based solely on sequence alignment. In the first 
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theoretical model deposited in the protein data bank, PDB 1O0J, the two tryptophans are 
located on the exterior of the protein. This is illustrated in Figure 6.5 where the Trp98 is 
shown as purple sticks in a top down view of the protease. This first model was based 
on our first (S1) homology alignment (Herger, 2004; Shuker et al., 2003). 
 
Figure 6.5 Top down view of PDB 1O0J with tryptophans shown in purple. 
 
 
In the second theoretical model, PDB 1TP1, based on our revised (S2) alignment 
(Herger et al., 2004) the tryptophans are also located on the exterior of the protease. 
Figure 6.6 shows a top view of PDB 1TP1 with the tryptophans shown in purple. There 
are some rotational differences between the two tryptophans in each structure. Both are 
consistent with displaying the tryptophans as solvent exposed. However, in an earlier 
unpublished model based on the S1 alignment, the tryptophans are in the interior of the 
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protein. This model was also prepared using MODELLER.  Figure 6.7 shows this model 
with the buried tryptophans shown in purple. 
 






Figure 6.7 Unpublished theoretical model of HTLV-I protease (S1 alignment) with 





The question remained as to which of these structures most acurately depicts the 
location of the tryptophan residues. It is expected that the large hydrophobic tryptophans 









6.3 Alanine Scan of HTLV-I Protease 
 
 
 Recognizing which residues in an active site domain contribute to catalytic 
efficiency is important for understanding the structure and function of an enzyme. An 
alanine scan can be a critical diagnostic tool for identifying these residues (Cunningham 
& Wells, 1989). This technique involves mutating a putative active site residue to an 
alanine and then testing catalytic activity. Alanine is chosen because it is the smallest 
chiral amino acid. Bryan Herger prepared several constructs containing alanine 
mutations of sites that were speculated to be important for activity. These mutants were: 
Arg10, Leu30, Thr94, Lys95, Asn96, Trp98, and Ile100. Kinetic assays were performed with the 
MA/CA subrate analogue, APQVL(Nph)VMHPL, where Nph is 4-nitrophenylalanine. 









   
 101 
 Table 6.2  Kinetic Results of Alanine Mutants. 
Mutant kcat (s-1) KM (µM) kcat/KM (M
-1 s-1) Whole 
number 
ratio 
L40I 2.74 x 10-3 43.2 63.5 

R10A 7.18 x 10-3 61.6 117 

L30A 5.72 x 10-3 71.6 79.9 

T94A 3.01 x 10-3 111 27.2 

K95A 9.36 x 10-3 73.6 127 

N96A 6.03 x 10-3 70.3 85.7 

W98A 2.96 x 10-3 8.33 355 





The kcat/KM  is the apparent second-order rate constant for the enzyme to catalyze 
transformation of the substrate into product. Therefore, it can be used as a measure of 
catalytic efficiency for the enzyme (Garrett & Grisham, 1995). The threonine mutation 
was the only one to reduce catalyitic activity with a kcat/KM of 27.2 M-1s-1. Thr94 may have 
a stabilizing function through hydrogen bonding to the P1 leucine of the substrate. The 
Ile100, Arg10, and Lys95 all increased the activity with kcat/KM of 102 M-1s-1, 117 M-1s-1, 127 
M-1s-1, respectively. The Trp98 mutation had a dramatic effect in increased protease 
activity with a kcat/KM of 355 M-1s-1. The KM value of 8.33 µM was the major contributor to 
this marked increase in activity. The KM is inversely proportional to the enzyme affinity 
for its substrate (Garrett & Grisham, 1995). Therefore, the loss of the tryptophans gives 
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the protease a higher affinity for the MA/CA substrate. This is significant because it 
suggests that the tryptophans must be located near the active site of the protein. Unlike 
other retroviral proteases, HTLV-I protease contains tryptophan residues at positions in 
proximity to residues Ile100-Ile101-Gly102, which are in the active site. The question still 
remained as to whether or not the tryptophans flank the active site and are solvent 




6.4 Fluorescent Quenching of HTLV-I Protease Tryptophan98 
 
 
A common method to determine the location of tryptophans is to use 
fluorescence quenching of the tryptophan residues. In proteins, tryptophan is typically 
the most dominant fluorophore present with an absorbance maximum near 280 nm. The 
emission maximum of tryptophan is very sensitive to the polarity of the surrounding 
environment. A tryptophan that is buried deep inside a protein has an emission 
maximum near 320 nm where as a solvent-exposed tryptophan has an emission 








6.4.1 Results from Quenching Experiments 
 
 
In acrylamide quenching experiments, a linear quenching of the tryptophan 
fluorescence peak is expected due to the ability of acrylamide to penetrate the interior of 
the protein in its native state. For KI quenching, there should be no reduction in the 
fluorescence peak for buried tryptophan residues in the native protein. However, once 
denatured, a reduction in the fluorescence tryptophan peak is expected because all 
tryptophan residues should be exposed.  
The effects of quenching of native HTLV-I tryptophans with acrylamide are 
shown in Figure 6.8. The most intense curve resulted in the absence of quencher. 
Subsequent dilutions with acrylamide led to considerable quenching at 350 nm. Because 
acrylamide is hydrophobic, it is able to penetrate the folded protein and  interact with the 
tryptophan residues allowing for adequate quenching of the fluorophores. Dilutions of KI 
into the native protease solution were carried out (Figure 6.9). For this case, the least 
intense curve is the one with no KI added. Rather than quenching, there is an increasing 
fluorescence with increasing KI due to the fluorescence of iodine. The increase in signal 
upon KI additions can be attributed to the free I3- in solution, which has an absorbance in 
the wavelength region of tryptophan residues. When the protease was denatured 
however, we saw considerable quenching as is shown in Figure 6.10. Again, the most 
intense curve resulted is without any KI and subsequent quenching can be seen as 
higher concentrations of KI are added to the solution. From quenching the experiments 
with KI, the fact that KI does not quench the tryptophans in the native protease, but does 
 104 
quench the denatured protease, indicates that the two tryptophans are buried within the 






































































































































































































A quantitative analysis of collisional fluorescence quenching can be carried out 
according to the modified Stern-Volmer equation (Yi-Brunozzi et al., 2001; Weber & 




= KSV [Q]       (Eq. 1) 
and F are the fluorescence intensities in the absence and presence of quencher, 
respectively,  [Q] is the concentration of quencher, V is the static quenching constant, 
and Ksv is the dynamic Stern-Volmer constant. The fluorescence intensity can be written 
in terms of the sum of fluorophores exposed to solvent, 
 
ba FFF ,0,00 +=       (Eq. 2) 
 
where Fo,a and Fo,b are the individual initial intensities related to each species. The 
fraction of the initial fluorophores accessible to quencher can be determined using a 
modified Stern-Volmer equation (Eftink & Ghiron, 1977; Eftink & Ghiron, 1976; Yi-
Brunozzi et al., 2001), 
 







     (Eq. 3) 
 
where fa is the fraction of accessible fluorophores. For nonlinearity, our data were fitted 
using PSI-Plot (Poly Software International) to distinguish between the sphere-of-action 
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static quenching and multiple fluorophore models. The static sphere-of-action quenching 
model was derived from the equation, 
 
][0 ][1 QVSV eQKF
F
+=       (Eq. 4) 
where V is the static quenching component (Weber & Senior, 2000; Yi-Brunozzi et al., 
2001). For multiple fluorophores (i.e. two tryptophans, one per monomer) where there 









a [Q]( )1− fa( )+ fa
     (Eq. 5) 
 







a =       (Eq. 6)  
 
relates the fraction of initial fluoresence emitted by one species present (see Eq. 3) with 
its Stern-Volmer constant: aSVK . 
Even though it appears that the tryptophans are internal by qualitative analysis, 
analysis of the fluorescence at 350 nm using the linear Stern-Volmer by plotting equation 
Fo/F vs. [KI] or [acrylamide] (Eq. 1) did not give linear results. As shown in Figure 6.11, 
acrylamide quenching resulted in a concave downward slope and KI quenching gave a 
concave upward slope. Nonlinear Stern-Volmer plots indicate that there is heterogeneity 
























Figure 6.11  Relative corrected intensity ratio (Fo/F) vs. quencher concentration ([Q]) in 
M). The upper curve (pink ) represents the quenching denatured protease with KI and 
the lower curve  (blue ) represents acrylamide quenching of native protease. 
 
 
Deviation from linearity will occur due to multiple fluorescing centers. They 
results here suggest that the two tryptophans in the dimer have varying degrees of 
accessibility to the quencher. In HTLV-I protease, the tryptophan residue of one 
monomer may be more buried than the tryptophan on the other. 
Employing the modified Stern-Volmer  equation, Fo/(Fo - F) vs. 1/[Q] (Eq. 3) was 
plotted (Figure 6.12) where the reciprocal of the y-intercept is equal to fa ,which pertains 
to the fraction of accessible fluorophores. This plot yielded fractions of 80% accessible 
fluorophores for KI quenching and 92% for acrylamide. The fraction of accessible 
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fluorophores for KI quenching of the denatured enzyme should be equal to 1 because all 
tryptophan residues would be accessible to KI in the denatured state. It is not known 
















Figure 6.12 Modified Stern-Volmer plots for acrylamide quenching of folded HTLV-I 




The 92% accessibility of the tryptophans to acrylamide quenching suggests that 
the fluorophores do not behave homogeneously and most likely have slight differences 
in orientation. In fact, HTLV-I protease is probably not a truly C2 symmetric homodimer. 
Other retroviral proteases such as HIV-1 and RSV are known to fit pseudo-C2 point 




















(Tözsér et al., 2000; Prabu-Jeyabalan et al., 2000). It may be that retroviral proteases in 
the absence of substrate are asymmetric dimers in vivo. In this case, based on 
sequence alignment with other aspartyl proteases, HTLV-I would also confer a pseudo-
C2 symmetry. If so, it is highly likely that the two tryptophans have significant 
translational differences resulting in equivalent but non-interacting fluorescence by these 
residues. Using PSI-Plot (Poly Software International) the data were fitted to the sphere-
of-action static quenching model (Eq. 4) for KI and to the multiple fluorophore model (Eq. 






















Figure 6.13  Plot employing fitted multiple fluorophore model for acrylamide quenching 
of folded HTLV-I protease and static sphere-of-action model for KI quenching of 
denatured protease. 
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The data from KI and acrylamide were fitted to both Eqs. 4 and 5. The best-fits 
were found to apply to static quenching for KI and multiple fluorophore model for 
acrylamide quenching.  
The KSV can be found for acrylamide quenching from the plot in Figure 6.13, 
where the slope is equal to 1/faKSV. The KSV for acrylamide quenching was found to be 
1.96 M-1. This is in agreement with the range of several other enzymes shown in Table 
6.3 (Eftink and Ghiron, 1977). 
 
 
Table 6.3  Acrylamide Quenching KSV for Several Enzymes. 




R Nase T1 1.1 
 
 
6.4.2 Conclusions from Quenching Studies 
 
 
 From the fluorescence results, the acrylamide and KI quenching showed 
deviations from linearity, which imply that there are multiple fluorescing centers. The 
acrylamide quenching on native protease was fitted to the multiple fluorophore model 
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and yielded 92% accessibility to the quencher. This suggests slight rotational differences 
between the two tryptophans (one per dimer).  
From the KI quenching results on both native and denatured protease, it can be 
concluded that the theoretical models deposited in the protein data bank are inaccurate 
representations due to the location of the Trp98 residues. The lack of quenching by KI in 
the native protease and positive quenching in denatured protease indicate that the 
tryptophan residues are indeed in the interior of the protein.  Theoretical models are 
important tools for better understanding of structure when three-dimensional crystal 
structures are not available. However, theoretical models must be constantly updated as 
more information becomes available regarding structure.  
 Of major significance in this study is that quenching by KI provides a quick 
analytical tool for determining whether or not HTLV-I protease is folded. Before NMR 
samples are prepared, KI quenching experiments can be run on protease samples to 
validate whether the protease is suitable for structure experiments. 
 
 
6.5 Structure Determination by NMR 
 
 
The three dimensional structure of HTLV-I protease is critical for accurate 
representation of enzymology. However, to date no X-ray or NMR structure has been 
reported. It has been a primary goal of the Shuker group to obtain a three-dimensional 
structure of HTLV-I protease. The work of structure determination has been in 
collaboration with Dr. Alex Wlodawer at the National Cancer Institute (Frederick, MD) for 
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the X-ray structure, Dr.’s Vicky Bevilacqua and Jeffrey Rice at Edgewood Chemical 
Biological Center (Aberdeen Proving Ground, MD) and Mike Goeger of the New York 












Below in Figures 6.14 and 6.15 are 800 MHz NMR spectra obtained at the 
NYSBC. These data are similar to those seen in previous experiments carried out by 








Figure 6.14  HTLV-I protease 800 MHz 1D 1H NMR  amide (100 µM 





Figure  6.15  HTLV-I protease HSQC after 1 hour of processing (100 µM 




 A properly folded protein of this molecular weight should a number of 
well-resolved amide peaks above 8.5 parts per million (ppm) and below 6.5 ppm. 
These peaks evident in the 1D spectrum and the related chemical shifts would 
result in peaks spread throughout the HSQC spectrum. The lack of such 
resolution in the spectra shown here is primarily occupying a random coil 
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structure under these conditions (100 µM [protease], 50 mM sodium acetate, 1 
mM DTT, and pH 5.3). 
     
 
6.7 Conclusions  
 
 
There are significant problems that must be addressed in order to obtain 
a correctly folded enzyme. First, HTLV-I protease is comprised of mostly 
hydrophobic residues. There are expected to be many phenylalanine residues 
exposed to the exterior of the protein. These may complicate the structure by 
facilitating aggregation. Second, the issue of properly folding the protein has not 
been resolved. The protease remains active in a partially folded state so that 
kinetic experiments demonstrate definable differences between various 
substrates and inhibitors. However, as revealed from repeated KI quenching 
experiments prepared following the same conditions, the protease is only folded 
10-20% of the time. In addition, it appears from the MALDI results for the C-
terminal cleavage data, that there is an additional autoprocessing site at Leu78. 
The autoprocessing of this site may result in the denaturing of the protease, 
which may account for the random coil NMR data. 
The main step toward obtaining an NMR structure is to have adequate 
amounts of labeled protein. We were able to express enough 15N-labeled protein 
so that an HSQC spectrum with reasonable signal-to-noise could be obtained in 
approximately one hour. Perhaps, an L40I-L78I mutant can be 15N-labeled and 
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expressed. This may be the next step toward having HTLV-I protease stable 
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    All retroviruses, except spumaviruses, have nucleocapsid proteins that contain 
one or two zinc fingers with a highly conserved CX2CX4HX4C (CCHC) motif where C = 
cysteine, H = histidine, and X = any amino acid (Amarasinghe et al., 2000; Coffin et al., 
1997; Lee et al., 1998; Williams et al., 2002). Each CCHC binds a zinc atom as 
illustrated in Figure 7.1. This figure shows HIV nucleocapsid structure with the bound 
zinc atoms. 
  The nucleocapsid is cleaved from the Gag polyprecursor and has its primary 
function in packaging the viral genome (Bertola et al., 2000; Coffin et al., 1997; Stephen 
et al., 2002). Within the Gag precursor, the nucleocapsid domain is involved in both 
recognition and packaging the RNA. Figure 7.2 shows a typical retroviral nucleocapsid 
CCHC interaction with RNA. 
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Figure 7.1 HIV nucleocapsid (PDB 1mfs) Lee, et al. (1998) J. Mol. Biol. 279, 633-649. 




Figure 7.2 HIV nucleocapsid bound to RNA (PDB 1mfs) Lee, et al. (1998) J. Mol. Biol.          





Figure 7.3 shows the sequence alignment of HIV-1 and HTLV-I nucleocapsids. 
The two nucleocapsids share only 16% homology. HTLV-I nucleocapsid has a much 
longer C-terminal region. This most likely has to due with specific packaging of the RNA 





HTLV-I    VVQPKKPPPNQP----CFRCGKAGHWSRDCTQPRPPP 
HIV      -MQ-KGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKK- 
 
HTLV-I    GPCPLCQDPTHWKRDCPRLKPTIPEPEPEEDALLL 





14/85 = 16% 
 
W/O TAIL 
     14/55 = 25% 
 




Little is known about HTLV-I nucleocapsid. However, HIV-1 nucleocapsid has 
shown promise as a possible candidate for inhibitors (Stephen et al., 2002; Turpin et al., 
1999).  Determination of the structure of HTLV-I nucleocapsid may be crucial to finding 









 HTLV-I genome K30 plasmid was generously provided by Dr. Michele Owen 
from the Centers for Disease Control & Prevention (CDC) and by Dr. Thomas J. Kindt 
from the National Institutes of Health (NIH). The HTLV-I gag precursor gene, in the K30 
plasmid, is contained within the reading frame of base pairs 804 to 2099 (Zhao et al., 
1993). Primers that contain XhoI and NdeI (New England Biolabs) restriction sites were 
designed to express the gag gene and the nucleocapsid gene (base pairs 1838-2099) 
from the HTLV-I genome (Table 7.1) and amplification was performed by polymerase 
chain reaction (PCR).  Since the 5’ end of the nucleocapsid gene is synonymous with the 
5’ end of the Gag precursor polyprotein gene, the reverse Gag primer was used for the 
nucleocapsid expression plasmid as well as Gag expression plasmid. The amplified 
products were isolated from 1% agarose using the Qiagen system, digested with XhoI 
and NdeI and subcloned into pET-28b(+) plasmid (Novagen), which contains a His-tag 




Table 7.1  PCR primers for construction of pNC1 and pGag1. The NdeI are red, the 
XhoI is blue, and the ↓ is the cleavage site. 
Plasmid Primer Sequence 










  Following PCR amplification using the primers listed in Table 7.1 agarose 
electrophoresis gel was carried out on the purified fragments. A band the size of NC 
DNA was identified (261 base pairs). The Gag precursor DNA showed more than one 
fragment that may be the result of non-specific binding. However, a band was identified 
at the expected size of the Gag amplicon (1295 base pairs), but was not purified further. 
The NC amplicon was inserted into pET-28b(+). Following gel extraction and purification, 
an agarose gel showed a band containing both the pET-28b(+) and NC insert. The 
ligation was thus successful and a stock solution of the NC plasmid was transformed into 
JM109 cells was prepared. Several LB growths were carried out and attempts made to 
purify NC on a nickel affinity column. However, none of the protein gels indicated the 






The amplification of the Gag amplicon was accomplished. However, the band 
identified for the Gag amplicon was not purified and no ligation was attempted. NC was 
successfully inserted into pET-28b(+). Protein gels after several LB growths followed by 
purification attempts via nickel affinity column failed to show any indication of NC. 
However, the NC protein may be present below the detection limit. A more reasonable 
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explanation is that the NC begins to fold upon expression and forms a three-dimensional 
structure, in which the His-tag is buried. If the His-tag is buried within the protein, it 
cannot bind to the nickel column and will be lost in the flow-through. Bryan Herger 
attempted to express NC in the Rosetta cell line. SDS PAGE data revealed that the 
expected protein band was present. However, he was also unable to isolate the protein. 
Future work with NC expression and isolation may be more efficiently done with other 
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CONCLUSIONS AND FUTURE WORK 
 
 
The primary goals of this research are to further the understanding of  the virology 
and enzymology of human T-cell leukemia virus type I (HTLV-I) that will lead to the 
development of treatments for patients infected with HTLV-I. HTLV-I is an oncogenic 
virus of the Retroviridae family (Murphy & Kingsbury, 1990) and is the causative agent of 
adult T-cell leukemia/lymphoma (ATL) (Gitlin et al., 1993), and tropical spastic 
paraparesis/HTLV-I associated myelopathy (TSP/HAM) (Gessain et al., 1985). HTLV-I 
has been classified as a dangerous emerging pathogen by the Centers for Disease 
Control & Prevention (Ewald, 1996; Satcher, 1995). HTLV-I is endemic in southwestern 
Japan (Gallo & Thomson, 1996; Green & Chen, 1993), as well as areas in the 
Carribean, sub-Saharan Africa, Seychelles Islands, Melanesia, Australia, Philippines, the 
Americas, south India, and southwestern Asia (Gallo & Thomson, 1996). World-wide 
estimates are that approximately 20 million persons are infected with HTLV-I (Dekaban 
et al., 1992). In the United States, there is an estimated prevalence of 0.016-0.1% 
HTLV-I infection among blood donors (Zucker-Franklin & Pancake, 1998). Transmission 
is vertical via maternal breast milk, intravenous drug use with contaminated sharps, 
transfusion with infected blood, and sexual transmission (Gessain, 1996; Kaplan & 
Khabbaz, 1993; Khabbaz et al., 1990).  
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Currently, there is no adequate treatment for HTLV-I infected individuals. 
Combination therapies have been tried, with limited success. The median survival time 
of infected patients with acute ATL is 7-8 months (Matsushita et al., 1999). The fact that 
there are currently no effective treatments to control HTLV-I infection and prevent or 
treat HTLV-I induced ATL and TSP/HAM is obviously a significant problem. 
HTLV-I protease is necessary for retroviral maturation and replication and is, 
therefore, an attractive target for inhibitor design.  Understanding the structure and 
enzymology of HTLV-I protease is important for the design of inhibitors. The last ten 
residues of HTLV-I protease are only found in leukemia virus proteases. It was found 
that the last ten residues are not necessary for enzymatic activity. HTLV-I has a putative 
natural cleavage junction in the C-terminal region. The C-terminal cleavage appeared to 
be inhibited by Tyr114 or Glu117.  Studies with synthetic peptide mutants showed that the 
C-terminal “tail” was inhibited by Glu117.  HTLV-I protease mutants incorporating either a 
Y114V or E117V mutations were incubated at 37 °C and cleavage products confirmed 
by MALDI. The data confirm the Glu117 inhibition. In addition, a second autoprocessing 
site was found at Leu78.  
Investigation of peptide mimetic compounds incorporating the tetrahedral 
intermediate of aspartyl protease catalyzed cleavage are crucial for the development of 
lead inhibitors. Compounds containing statine (Sta), 4-amino-3-hydroxy-5-
phenylpentanoic acid (AHPPA), or hydroxyethylamine (HEA) were expected to be potent 
protease inhibitors with Ki < 1 nM.  
This was not the case. Our best inhibitor, the MA/CA statine-based inhibitor (Ac-
QV-Sta-PV) had the inhibition constant (Ki = 29 ± 4 nM). This was comparable to the 
CS-I-25 pepsin inhibitor with Ki = 30 ± 3 nM.  Percent inhibition was also similar for these 
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two inhibitors with 88% inhibition for Ac-QV-Sta-PV and 86% for CS-I-25. These peptide 
inhibitors still provide preliminary information that can be used to develop non-peptide 
inhibitors that have better bioavailability and pharmacokinetics. In addition, modifications 
of the HEA inhibitors studied here could be developed that are more efficient inhibitors. 
Akaji et al. synthesized an hydroxyethylamine inhibitor with a Ki = 38 ± 8 nM (Akaji et al., 
2003), which is in the experimental range of our statine compound.  
In vitro cell culture of HTLV-I protease inhibition began to show slight inhibition 
after five weeks. Both the Ac-QV-Sta-PV and the Ac-QV-AHPPA-PV showed inhibition 
with concentrations of 5 and 10 µM. For both classes of inhibitors, the 20 µM 
concentrations did not appear to have any effect. However, the cell culture assays will 
monitored continuously to determine whether the peptides actually inhibit the virus or if 
results are due to cytotoxicity. In either case, the results are significant toward our 
understanding of antiviral therapy for of the HTLV-I. 
Understanding of HTLV-I protease structure and enzymology is crucial for the 
design of inhibitors. The last ten residues of HTLV-I protease are only found in leukemia 
virus proteases. HTLV-I has a nature cleavage junction at the last ten residues in the C-
terminal region. When we have the final LC-MS data on the C-terminal tail cleavage, this 
will confirm that the C-terminal tail is not cleaved due to the electrostatic effects of Glu117. 
It is believed that this C-terminal tail is an artifact as a result of a point mutation. In vitro 
studies with our HTLV-I mutants could provide us with further understanding of the 











9.1  HTLV-I Protease C-Terminal Cleavage Junction 
 
 
9.1.1 Preparation and Purification of HTLV-I Protease 
 
 
Chemicals. Imidazole was purchased from Sigma, and Tris, urea, sodium acetate, and 
Luria-Bertani (LB broth) from Fisher. All chemicals were of reagent grade and used 
without further purification. Microsep concentrators were purchased from Pall Filtron 
Corporation. The water used in all experiments was deionized and filtered using a 
NANOpure Infinity base unit from Barnstead/Thermolyne Corporation. 
Protease purification. The construct pPR106 containing the DNA encoding HTLV-I 
protease (Shuker et al., 2003)was transformed into E. coli BL21(DE3) (Novagen) and 
expressed by growth in LB (Miller) liquid media inoculated with 500 µL ampicillin (100 
mg/mL). The cells were grown at 37 °C to an optical density at 600 nm (OD600) of 0.6-0.8 
followed by induction with isopropyl β-D-thiogalactoside (IPTG) to 0.4 mM final 
concentration. After incubation for 3 h, the cells were harvested by centrifugation at 
10,000g using a DuPont Sorvall RC-5B centrifuge for 5 min at 4 °C. The pellets were 
 134 
either stored at – 80 °C or resuspended in buffer A (20 mM Tris, pH 7.9, 5 mM 
imidazole, and 500 mM NaCl) then sonicated on ice followed by centrifugation at 
10,000g for 10 min. The insoluble fraction was collected by centrifugation at 10,000g for 
15 min. These steps were repeated. The pellet was resuspended in buffer B (buffer A 
augmented with 8 M urea) and incubated at 4 °C for 1 h. The mixture was separated by 
centrifugation at 14,000g for 45 min. The supernatant was loaded on a 4 mL His-Bind 
resin (Novagen) column charged with 0.5 M nickel sulfate. The resin-bound protease 
was washed with buffer B followed by buffer C (20 mM Tris, pH 7.9, 20 mM imidazole, 
500 mM NaCl, and 8 M urea). The protease was eluted with buffer D (20 mM Tris, pH 
7.9, 1 M imidazole, 500 mM NaCl, and 8 M urea). Purified protease was dialyzed in 10 
mM acetic acid (pH 5.3). 
 
 




C-terminal cleavage site peptide mutants. Two single mutant peptides pertaining to 
Y114V and E117V (NH2-VLVLPEAKGP-OH and NH2-VLYLPVAKGP-OH, respectively) 
and one double mutant containing both Y114V and E117V (NH2-VLVLPVAK-OH) were 
purchased from SynPep. Four mg samples of each peptide were dissolved in 100 µL 
dimethyl sulfoxide (DMSO) then 100 µL of 10 mM NaOAc, pH 5.2 buffer (Buffer N) 
containing 1 mM dithiothreitol (DTT) was added. This was followed by the addition of 
500 µL of 85 µM protease in Buffer N. The solution was incubated for 3 h at 37 °C and 
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then passed through a MicroSep concentrator membrane (Pall Gelman) with a 3000 Da 
cutoff at 5000g for 3 h to further purify the protease. The flow-through solution containing 





9.2 Solid Phase Synthesis 
 
 
9.2.1 Synthesis of Statine and AHPPA Inhibitors 
 
 
Solid Phase Synthesis of Compounds 1-6 using ArgoPore-NH2 Resin. AgroPore-NH2 
resin (Argonaut Technologies Inc.) with a reported substitution of 0.75 mmol/g resin was 
used (Wellings & Atherton, 1997). To each column, HMBA was attached to the bead as 
a cleavable linker. Then the Fmoc-protected amino acid was attached to the linker by 
forming the symmetrical anhydride. To prepare the Fmoc-protected amino acid for 
attachment, ten equivalents of the Fmoc-amino acid were placed in a round bottom flask 
in N,N-dimethylformamide (DMF). Five equivalents of N,N’-dicyclohexylcarbodiimide 
(DCC) were added and the mixture was stired under N2 gas for 20 min at 0 °C. The 
solution was filtered and added to the HMBA-linked beads in each column. A catalytic 
amount of 4-dimethylaminopyridine (DMAP) was added and the reaction was allowed to 
continue over night on the rotisserie. The Fmoc was cleaved with 20% piperidine in DMF 
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(mechanism shown in Figure 5.4). Following deprotection, the next amino acid was 
added by base catalysis with DIPEA and the coupling agent TBTU for the ester-linked 
amino acids and HBTU for subsequent amino acids. Briefly, 2.5 molar equivalents of the 
Fmoc-amino acid and 3 molar equivalents of the coupling reagent (TBTU or HBTU) were 
dissolved in a minimal amount of DMF.  Then this solution was added to the resin 
followed by the addition of 5 molar equivalents of DIPEA. The reaction was sealed and 
rotated for no less then 3 hours. Each coupling step was repeated two times. After 
coupling, the beads were rinsed with DMF followed by DCM.  The Fmoc protecting 
group was cleaved with two successive 20 minute treatments of the resin with a 20% 
solution of piperidine in DMF. Efficiency of coupling was monitored via a 2,4,6-
trinitrobenzencesulfonic acid (TNBS) test between each step (Hancock & Battrsby, 1976; 
Wellings & Atherton, 1997). Capping was performed in between each coupling with a 
solution of 5% acetic anhydride and 4 equivalents of DIPEA in DMF. Upon completion of 
synthesis, the side-chain protecting groups were cleaved with a solution of 95% TFA, 
2.5% phenol, and 2.5% H2O for 25-min. Peptides were cleaved from the beads with 50% 
ethylamine in acetonitrile. 
 
Solid Phase Synthesis of Compounds 1-6 using NovaSyn® TG HMBA Resin.  
NovaSyn® TG HMBA Resin (Novabiochem) with a reported substitution of 0.69 mmol/g 
resin was used (Sheppard, 1982). To each bead, the Fmoc-protected amino acid was 
attached to the linker and deprotected as described above. Following deprotection, the 
next amino acid was added by base catalysis. Briefly, 2.5 molar equivalents of the 
Fmoc-amino acid, 4 molar equivalents of the coupling reagent TBTU, and 4 molar 
equivalents of N-hydroxybenzotrialoze (HOBt) were dissolved in a minimal amount of 
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DMF.  Then this solution was added to the resin followed by the addition of 5 molar 
equivalents of DIPEA. The reaction was sealed and rotated overnight. The remainder of 
the synthesis followed the same procedure as for the Argopore-NH2 resin, except that 
peptides were cleaved from beads with 50% methanol in triethylamine (TEA). 
 
Solid Phase Synthesis of Compounds 1-6 using NovaSyn® TGA Pre-loaded Resin. 
NovaSyn® TGA N-α-Fmoc protected-Val(Ile) resin (Novabiochem) with a reported 
substitution of 0.24 mmol/g for Val-substituted resin and 0.21 mmol/g for Ile-substituted 
resin was used (Sheppard, 1982; Bayer, 1991). The beads were deprotected with 20% 
piperidine. Following deprotection, the remainder of the synthesis followed the same 
procedure as for the NovaSyn® TG resin except the side-chain protecting groups were 
cleaved along with release of peptides from beads with a solution of 95% TFA, 5% H2O 
for 30-min. Results were confirmed by LC/MS. 
 
 
9.2.2 Synthesis of HEA Inhibitors 
  
 
Compound 13. A trial reaction to link TPCK to Pro was first carried out to confirm that the 
reaction between TPCK and Pro would proceed prior to addition of TPCK to the Pro-
linked beads. For the trial reaction, to a 25 mL boiling flask, 1 equivalent of TPCK was 
added to 25 mL DMF along with NaI (2 eq). Proline (2.5 eq) was then added followed by 
NaHCO3 (2.5 eq) and DIPEA (5 eq). The components did not dissolve entirely. Water 
was added until all the components dissolved. The reaction was allowed to stir for 48 
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hours. Comfirmatiion of the synthesis of compound 13 was verified by comparison of 1H 
NMR chemical shifts for the TPCK starting material (Figure 9.1 Compound 10) and for 
the TPCK-Pro product (Figure 9.2 Compound 13). There was an upfield shift in the 
methylene protons from δ 4.25 for 10 to overlapping the β protons at δ 3.42 for 13 and 
the appearance of the hydroxyl on the proline at δ 10.60 for 13. 
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11 10 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0
ppm  
Figure 9.1 1H NMR spectrum of starting material TPCK. Chemical shift assignments: δ 
7.31-7.45 (m, 9 H, ArH), δ 4.52 (t, 1H, NHCHCH2), δ 4.25 (dd, 2H, COCH2Cl), δ 3.35 
(acetone), δ 2.52-2.90 (dd, 2H, CH2CH), δ 2.50 (DMSO), δ 2.35 (s, 3H, CH3Ar), δ 2.10 








11 10 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0
ppm  
Figure 9.2 1H NMR spectrum of Tos-TPCK-Pro (13) product. Chemical shift 
assignments: δ 10.60 (s, 1H, COOH), δ 7.25-7.56 (m, 9H, ArH), δ 4.52 (t, 1H, 
NHCHCH2), δ 3.50 (s, 1H, NHCHCOOH), δ 3.42 (dd, 2H, COCH2N), δ 3.35 (Acetone), δ 











Solid phase synthesis of HEA inhibitors 7-8. The HEA inhibitors were synthesized as 
above for compounds 1-6 on NovaSyn® TGA N-α-Fmoc protected-Val(Ile) resin 
(Novabiochem) for to the proline residue (Pro-Val(Ile)-HMBA-). Next, 1 equivalent of 
TPCK was added along with 1 mL DMF and  NaI (2 eq). Following the synthesis for 
Comound 13, proline (2.5 eq) was added followed by NaHCO3 (2.5 eq) and DIPEA (5 
eq). Water was added to dissolve the components. However, they did not dissolved 
entirely. The reaction was allowed to mix on the rotisserie for 48 hours. Once the 
reaction was completed, the TPCK was removed. This was accomplished by adding the 
beads to a small round bottom flask in ethanol. Ten equivalents of NaBH4 and 4 
equivalents of 1,2-dimethoxynaphthalene were added. The mixture was stirred overnight 
under N2 gas and a 600 watt sunlamp was used as the light source for the electron 
transfer reaction. TPCK removal was confirmed by a TNBS test and the synthesis of the 
peptides were continued in the same manner as for the statine and AHPPA inhibitors. 
Results were confirmed by LC/MS. 
 
 
9.3 FRET Inhibition Assays 
 
 
Inhibition Assays. Inhibitors were assayed with varying concentrations of Dabcyl-
PQVLPVMH-EDANS, a FRET substrate that absorbs at 340 nm and fluoresces at 490 
nm on cleavage.  HTLV-I protease (5 nM) was incubated with inhibitor (1-5 µM) for 5-20 
min at 37 oC on a 96-well Costar plate in 300 µL volumes containing 10% DMSO and 
Buffer N (pH 5.2, 400 mM NaOAc). The substrate was added (10-20 µM) and the 
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fluorescence was read on a ULTRA plate reader (TECAN) with excitation 340 nm. The 
background correction was done using a well with that contained substrate, DMSO, and 
buffer. An example of the results is shown in Figure 9.3. Initial time points during which 
























Figure 9.3 Data showing increasing fluorescence of inhibitors and substrate. 
Inhibitors are color-coded in the following manener: Red (Ac-QV-Sta-PV), 
Orange (Ac-QV-AHPPA-PV), Yellow (Ac-SI-Sta-PV), Green (Ac-SI-AHPPA-
PV), Blue (Ac-VI-Sta-PI), Purple (Ac-VI-AHPPA-PI), Pink (Ac-QV-F-HEA-PV), 






The velocity was found by taking the slope of each line for each inhibitor. Percent 
inhibition was calculated by dividing the intensity for the substrate in the presence of 
inhibitor by the intensity for the substrate alone using the following equation: (1- 
(Fi/Fs)*100), where Fi is the fluorescence intensity of the substrate in the presence of 
inhibitor and Fs is the fluorescence intensity of the substrate alone. 
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The inhibition constants were determined by a method developed by Dixon 
(Segal, 1975) where substrate and inhibitor concentrations are varied and plotted as 1/V 
vs. [Inhibitor]. An example of a data set is shown below in Figure 9.4. 
 
    velocity     1/V    
  [Substrate] 
10 













  0 0.895 1.030 1.090 1.150 1.12 0.97 0.92 0.87 
  1 0.111 0.715 0.648 0.256  1.39 1.54 3.91 
[Inhibitor] 1.33 0.344 0.323 0.350 0.112 2.91 3.10 2.86 8.93 
uM 3 0.166   0.452 6.02     
  5 0.086 0.370 0.478   11.63   20.33 
  2  0.180 0.826    5.56    
 





































9.4 HTLV-I Infection 
 
 
Cell Culture. Human T-cell lines from Hut-78 cell were cultured in a 5% CO2 incubator at 
37 °C using RPMI-1640 media supplemented with 10% fetal calf serum, 100 U/mL 
penicillin, 100 µg/mL streptomycin, and 2 mM L-glutamine (Gibco Laboratories, Grand 
Island, NY).  Cell cultures were split 1:10 twice weekly. This protocol was done to insure 
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that proper handling and maintenance of cell lines could be accomplished before working 
with HTLV-infected cell lines. 
 
Co-Infection of PBMCs with Hut-102 and MT-2 Cell Lines infected with HTLV-I. Three 
days prior to setting the infection, two vials of normal, uninfected donor PBMCs were 
thawed. Cells were counted and placed in a in a T150 flask at 106 cells/ml in RPMI-10% 
FCS, 10% IL-2.  Phytohemaglutinin (PHA) to a concentration of 0.1% PHA (1µl PHA / ml 
of medium) was added to stimulate growth of PBMCs.  The flask was incubated for 3 
days to activate the PBMCs.  The cell number was doubled during the three days to an 
approximate concentration of 2x106/ml. Approximately 3 mL of PHA-blasted PBMCs 
were removed from the T150 flasks and centrifuged at 1200 RPM for 10 minutes.  The 
supernatants were removed and resuspended in fresh medium so that the cells were 
again at 106 cells/ml in RPMI-10% FCS, 10% IL-2. HTLV-I-infected cells (HUT-102 and 
MT-2) were cultured in RPMI-10% FCS. The actively growing HUT-102 and MT-2 cells 
were counted using trypan blue in a hemacytomoter to determine cell viability. Cells 
were centrifuged and resuspended at 106 cells/ml in RPMI-10% FCS, 10% IL-2.  The 
HUT-102 and MT-2 cells were irradiated with 6,000 rads using a gamma cell irradiator. 
To a 24-well plate, PHA-blasted normal PBMC cells were added (106 cells/well in 1 mL). 
HUT-102 and MT-2 (HTLV-I-infected cells) were added to the normal donor PHA-blasted 
PBMCs in a 1:1 ratio for a total volume of 2 mL/well. In addition, one well was set 
containing only irradiated HUT-102 cells to monitor cell death. The cultures were 
maintained in RPMI-10% FCS, 10% IL-2 and supernatants were collected every 7th day 
to monitor infection by p19 antigen ELISA. The results of the first trial infection are 












































 The results in Table 9.1 indicate that the HUT-102 infections were successful as 
is seen by the re-emergence in p19 antigen absorbance after 21 days. The MT-2s do not 
show the increase in p19 antigen and thus the infection of MT-2 was not successful. The 
declining curve of the MT-2s show that the irradiated MT-2 cells die off without infection 
of PBMCs, which would show an increase in the p19 antigen as is shown for the HUT-
102 curves. However, the MT-2 data do show results that should be seen if the protease 







9.5 Inhibition of HTLV-I Protease in Cell Culture 
 
 
Inibition of HTLV-I in infected culture. The HUT-102 PBMC co-culture experiment was  
set up as previously described with the addition of 5, 10, or 20 µM concentrations of Ac-
QV-Sta-PV, CS-I-25, or with Leu-Leu-Leu tripeptide as a control. Inhibitors were diluted 
into RPMI from 10 mM stock solutions in DMSO. Supernatants were collected to monitor 
status of infection and fresh media replaced with inhibitor. Inhibitor concentrations were 
maintained throughout the culture and incubated at 37 °C. 
 
 
9.6   HTLV-I Protease Models 
 
 
Generation of Models. The programs MODELLER (Sali & Blundell, 1993; Marti-Renom 
et al., 2000; Fiser et al., 2000)] and Molecular Operating Environment (MOE) (Chemical 
Computing Group, Inc.) were used to generate structural models of HTLV-I protease 
with and without the ten C-terminal residues, using the sequence alignment generated 
by MODELLER and Protein Data Bank (PDB) structure files 1BAI (Wu et al., 1998) and 








9.7   Fluorescence Quenching of HTLV-I ProteaseTryptophan Residues 
 
 
Fluorescence quenching of HTLV-I tryptophans. Acrylamide quenching measurements 
at constant pH were carried out by monitoring the effect of increasing amounts of 
acrylamide (0-0.4 M) on solutions of HTLV-I protease in sodium acetate buffer (10 mM, 
pH 5.3). The KI quenching was similarly performed except that constant ionic strength 
was maintained using NaCl. A small amount of sodium thiosulfate (0.1 mM) was added 
to the KI solutions to prevent I3- formation, which absorbs within the wavelength region of 
tryptophan fluorescence (Eftink, 1991). However, this did not seem to have any effect on 
I3- formation. Fluorescence measurements were carried out on a Shimadzu RF 5301 PC 
spectrophotometer. Excitation was at 295 nm and fluorescence emission was scanned 
from 300 to 500 nm. Slit widths of 5.0 nm were set for both excitation and emission in all 
experiments. The data were corrected for background buffer fluorescence in the 
presence of 0 and highest quencher concentration. Dilution corrections were used to 
account for the addition of quencher. Finally, absorbance corrections were also made by 
taking the absorbance at 295 nm for HTLV-I protease with 0 and maximum amount of 




corr II =  the absorbance 











Plasmids. The following reagent was obtained through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH: HTLV-I K30 DNA from 
Dr. Thomas Kindt (Zhao et al., 1995). The pET-28b(+) vector was purchased from 
Novagen.  
Enzymes. Restriction endonucleases, Vent DNA polymerase, T4 DNA ligase, and 
calf intestinal alkaline phosphatase (CIP) were purchased from NEW England 
BioLabs.  
Oligos. Oligodeoxyribonucleotides were obtained from Stratagene. 















Two PCR reactions were set up to amplify the NC and Gag precursor DNA 
sequences from the HTLV-I K30 genome. In one microfuge tube, 10 µL 10X PCR buffer, 
100 mM MgSO4, 10 µL HTLV-I K30 template, 1 µL forward Gag primer (Table 7.1), 1 µL 
reverse Gag primer, 1µL dNTP, 0.5 µL DNA vent, and 74.5 µL deionized water were 
added. In a separate microfuge tube, 10 µL 10X PCR buffer, 100 mM MgSO4, 10 µL 
HTLV-I K30 template, 1 µL forward NC primer, 1 µL reverse Gag primer, 1µL dNTP, 0.5 
µL DNA vent, and 74.5 µL deionized water were added. The amplified DNA was purified 
using the Qiagen prep kit. An agarose gel was run to check for the 53 kDa Gag 
precursor and 9.5 kDa NC fragments. A 39 µL aliquot of the NC DNA was then 
incubated overnight in a solution of 5 µL 10X Buffer 2, 5 µL 10X BSA, and 1 µL of the 
XhoI restriction endonuclease. Another tube containing 39 µL of pET-28b(+) vector, 5 µL 
10X Buffer 2, 5 µL 10X BSA, and 1 µL of the XhoI endonuclease were simultaneously 
incubated overnight.  Both solutions were heat shocked at 70 oC for 20 min. followed by 
centrifugation. 1 µL of CIP was added to the pET-28b(+) solution to prevent self-ligation. 
Both solutions were incubated at 37 oC for 1 hr. Following incubation, the DNA was 
isolated on an agarose gel, extracted, and purified by the Qiagen prep method. Another 
agarose gel was run with the purified solutions to ensure that NC and pET-28b(+) DNA 
were present. Three microfuge tubes were labeled L1(ligation 1), L2 (ligation 2) and, LC 
(control). Reagents were added to the tubes according to Table 9.2. 
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Table 9.2 Reagent for pNC1 ligation. Two reactions (L1, L2) and a control (LC) were    
carried out. 






pET-28b(+) 10 5 10 
NC DNA insert 7 12  
dH2O - - 7 
10X T4 buffer 2 2 2 
dNTP 0.5 0.5 0.5 
T4 ligase 0.5 0.5 0.5 




All microfuge tubes containing the above solutions were incubated overnight at 4 
oC. The pET-28b(+) vector containing the nucleocapsid nucleotide sequence was named 
pNC1. An agarose gel was run to verify ligation. The pNC1 vector was transformed into 
JM109 cells. The JM109 cells were thawed on ice for 5 min. Three microfuge tubes were 
labeled L1, L2, and LC.  Four µL of pNC1 was added to the JM109 cells while set on ice. 
The cells were heat shocked at 42 oC for 40 s. To each of the three microfuge tubes, 800 
µL SOC was added followed by 200 µL JM109/pNC1solution. The solutions were 
incubated for 1 hr at 37 oC. Simultaneously, 3 Luria-Bertani (LB) agar plates containing 
kanimycin (Kan) (50 µg/mL) were incubated for 1 hr at 37 oC. Each culture plate was 
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